tenofovir has been researched along with Chronic Hepatitis B in 1000 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 88 (8.80) | 29.6817 |
| 2010's | 555 (55.50) | 24.3611 |
| 2020's | 357 (35.70) | 2.80 |
| Authors | Studies |
|---|---|
| Brunelle, MN; Holy, A; Lucifora, J; Neyts, J; Trepo, C; Villet, S; Zoulim, F | 1 |
| Boyd, A; Chas, J; Delaugerre, C; Dezanet, LNC; Gabassi, A; Lacombe, K; Lascoux-Combe, C; Maylin, S; Miailhes, P; Rougier, H | 1 |
| Ahn, SH; Chon, YE; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Lee, HA; Lee, HW; Park, JY; Park, SY; Roh, YH; Seo, YS; Tak, WY | 1 |
| Chen, L; Chen, W; Cui, H; Ding, Y; Gao, Y; Gong, H; Han, T; Jia, J; Jin, W; Jin, X; Jin, Z; Kong, F; Li, G; Liu, C; Liu, W; Mao, Q; Mu, M; Niu, J; Peng, Y; Shang, J; Song, X; Wang, D; Wang, P; Wen, X; Wu, X; Xia, J; Yan, X; Yang, Y; Yao, L; Zhang, D; Zhang, Z; Zhao, C; Zhu, Q | 1 |
| Burns, GS; Hall, SAL; Sundararajan, V; Thompson, A; Visvanathan, K; Vogrin, S; Wawryk, O | 1 |
| Krzowska-Firych, J; Pokora-Rodak, A; Tomasiewicz, K | 1 |
| Anderson, M; Bazinet, M; Cebotarescu, V; Cloherty, G; Cojuhari, L; Dittmer, U; Gersch, J; Holzmayer, V; Iarovoi, L; Jimbei, P; Jucov, A; Kuhns, M; Moscalu, I; Musteata, T; Pântea, V; Placinta, G; Smesnoi, V; Vaillant, A | 1 |
| Chen, E; Gao, Z; Gong, G; Gong, H; Hou, J; Hu, P; Huang, Y; Jin, Q; Li, C; Lin, S; Liu, Z; Mao, Q; Niu, J; Shang, J; Sun, C; Wang, F; Wen, X; Wu, G; Wu, Q; Xiao, L; Yang, D; Yao, L; Yin, H; Zhang, Y; Zhong, L | 1 |
| Choi, WM; Kim, WR; Lim, YS; Wong, GL; Yip, TC | 1 |
| Jin, YJ; Lee, JW; Lim, JH; Suh, YJ; Yu, JH | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yamashige, D | 1 |
| Ahn, SB; Berg, T; Buti, M; Calleja, JL; Cho, YK; Dalekos, GN; Goulis, J; Idilman, R; Jang, ES; Jang, MJ; Janssen, HLA; Jeong, SW; Jun, DW; Jung, YJ; Kim, HS; Kim, HY; Kim, SE; Kim, SU; Kim, YJ; Lampertico, P; Lee, HA; Lee, HC; Lee, JH; Lee, YB; Lim, YS; Manolakopoulos, S; Nam, JY; Papatheodoridis, GV; Park, SY; Seo, YS; Shim, JJ; Sinn, DH; Sohn, JH; Sypsa, V; Yoon, EL; Yoon, JH | 1 |
| Baik, SK; Cho, DH; Choi, J; Gwon, JG; Kang, SH; Kim, MY | 1 |
| Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML | 1 |
| An, H; Byun, KS; Jung, YK; Kim, JH; Kim, TH; Lee, YS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ; Yim, SY | 1 |
| Li, J; Li, X; Lin, L; Liu, Z; Mei, Y; Peng, L; Wu, L; Yuan, J; Zhu, S | 1 |
| Jeong, S; Kim, HI; Shin, HP | 1 |
| Feld, JJ; Gehring, AJ; Janssen, HLA; Kuipery, A; Mehrotra, A; Sanchez Vasquez, JD | 1 |
| Cai, DC; Hu, P; Ren, H; Zhang, Q | 1 |
| Brakenhoff, SM; Chan, HLY; Chen, CH; Chien, RN; Choi, HSJ; Cornberg, M; Feld, J; Forns, X; Hansen, BE; Hirode, G; Hsu, YC; Janssen, HLA; Jeng, WJ; Kao, JH; Lens, S; Papatheodoridi, M; Papatheodoridis, GV; Seto, WK; Sonneveld, MJ; Su, TH; Van Hees, S; Vanwolleghem, T; Wong, G; Yuen, MF | 1 |
| Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH | 1 |
| Chen, WC; Cheng, JS; Kao, SS; Li, YD; Li, YR; Lin, HS; Lu, CM; Sun, WC; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, HM; Yin, CH | 1 |
| Ahn, SB; Chen, CH; Cheung, R; Cho, YK; Chuang, WL; Dai, CY; Dao, A; Enomoto, M; Hoang, J; Huang, CF; Huang, DQ; Huang, JF; Huang, R; Hui, RW; Jeong, JY; Jeong, SW; Jun, DW; Khine, HHTW; Kim, HS; Kim, SE; Kozuka, R; Lee, DH; Lim, SG; Liu, L; Mak, LY; Nguyen, MH; Ogawa, E; Oh, H; Peng, CY; Quek, S; Shim, JJ; Trinh, H; Trinh, L; Tsai, PC; Tsui, V; Wong, GLH; Wu, C; Xie, Q; Yeh, ML; Yoon, E; Yu, ML; Yuen, MF | 1 |
| Furquim d'Almeida, A; Ho, E; Van Hees, S; Vanwolleghem, T | 1 |
| Fernández Cano, MC; Librero Jiménez, M; López Garrido, MÁ | 1 |
| Gao, P; Hou, J; Jia, J; Liang, X; Meng, Q; Ping, J; Shang, J; Sheng, J; Tang, H; Wang, G; Wang, H; Wu, S; Xie, Q; Xu, M; Zhang, J | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Peng, CY; Wang, JH | 1 |
| Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH | 1 |
| Chien, RN; Jeng, WJ; Liaw, YF; Liu, YC; Peng, CW | 1 |
| Dai, J; Jiang, K; Leng, S; Li, C; Qi, W; Ran, S; Shen, J; Wen, T; Zhang, Y | 1 |
| Jeong, J; Jung, SW; Park, EJ; Park, NH; Shin, JW | 1 |
| Chang, IW; Chen, CY; Gaggar, A; Hsu, YC; Huang, YT; Lin, JT; Nguyen, MH; Pan, DZ; Podlaha, O; Suri, V; Tseng, CH; Wu, CY | 1 |
| Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S | 1 |
| Han, N; Tang, H; Yan, LL | 1 |
| Ito, T; Kumada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Abiko, S; Kawagishi, N; Kimura, M; Kinoshita, K; Kitagataya, T; Maehara, O; Miyamoto, S; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Sho, T; Suda, G; Sugiura, R; Suzuki, K; Yamada, R; Yamamoto, Y | 1 |
| Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N | 2 |
| Huo, RR; Li, MJ; Li, RH; Papatheodoridis, G; Yuan, BH; Zhong, JH | 1 |
| Huang, DQ; Ishigami, M; Landis, CS; Liu, JK; Nguyen, MH; Vutien, P | 1 |
| Chokkalingam, AP; Flaherty, J; Gaggar, A; Gordon, SC; Jump, B; Kim, WR; Lu, M; Ramroth, H; Telep, LE | 1 |
| Chayanupatkul, M; Dilokthornsakul, P; Permsuwan, U; Sawangjit, R; Sriuttha, P; Sukeepaisarnjaroen, W; Tangkijvanich, P; Tanwandee, T | 1 |
| Chen, MS; Fu, YZ; Hou, JY; Hu, ZL; Li, WX; Wang, XH; Xu, L; Zhang, YJ; Zhou, QF; Zhou, ZG | 1 |
| Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H; Yamada, S | 1 |
| Lin, HY; Tseng, TC | 1 |
| Aghemo, A; Masetti, C; Pugliese, N; Viganò, M | 1 |
| Chien, RN; Liaw, YF | 2 |
| El-Serag, HB; Hsu, YC; Kanwal, F; Kim, H; Kramer, JR; Richardson, PA | 1 |
| Huang, SJ; Huang, Y; Huang, ZH; Liu, XH; Lu, GY; Qiu, LX; Su, YY; Wang, YB; Wu, T; Xia, NS; Yao, XM; Yuan, Q; Zhang, J; Zhong, GH | 1 |
| Adali, G; Bahadir, O; Degirmenci Salturk, AG; Doganay, HL; Gokcen, P; Guzelbulut, F; Kanatsiz, E; Kiyak, M; Ozdil, K; Ozturk, O | 1 |
| Choi, J; Choi, WM; Kim, KM; Lee, D; Lee, HC; Lim, J; Lim, YS; Shim, JH | 1 |
| Agarwal, K; Berg, T; Biermer, M; Carey, I; Lok, J; Lonjon-Domanec, I; Shivkar, Y | 1 |
| Afdhal, NH; Ankoma-Sey, V; Bae, H; Curry, MP; Dieterich, D; Frazier, L; Frick, A; Hann, HW; Kim, WR; Kwo, P; Milligan, S; Pan, CQ; Reddy, KR; Tong, MJ | 1 |
| Chen, M; Hou, J; Hu, Z; Wang, J; Xu, L; Zeng, H; Zhang, Y; Zhou, Z | 1 |
| Cho, JY; Choi, D; Choi, DL; Hong, G; Hwang, S; Kang, KJ; Kim, BW; Kim, DS; Kim, JM; Kim, MS; Lee, J; Lee, JG; Lee, KW; Moon, JI; Nah, YW; Ryu, JH; You, YK; Yu, HC | 1 |
| Chen, LW; Chien, CH; Chien, RN; Hu, CC; Huang, TS; Liang, KH; Lin, CL; Lin, YL; Shyu, YC; Yeh, CT | 1 |
| Bajpai, PS; Bukh, J; Dalegaard, MI; Fahnøe, U; Lundh, A; Ryom, L; Weis, N; Winckelmann, A | 1 |
| Jin, Y; Lu, L; Mao, Y; Wang, S; Yang, S; Yu, Y; Zhang, L; Zhao, A | 1 |
| Boglione, L; Chiecchio, M; D'Avolio, A; De Benedetto, I; De Nicolò, A; Di Perri, G; Dodaro, V | 1 |
| Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A | 1 |
| Cen, S; Gu, J; Liu, T; Sun, Q; Zhang, Q | 1 |
| Gedik, H | 1 |
| Rabenjanahary, TH; Rakotondrasoa, SR; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Chang, ML; Cheng, JS; Chien, RN; Lee, KC; Liaw, YF | 1 |
| Balkan, II; Bayramlar, OF; Karaali, R; Mete, B; Ozdemir, YE; Sahin Ozdemir, M; Saltoglu, N; Surme, S; Tabak, F; Yildiz Kaya, S | 1 |
| Agorastou, P; Dalekos, GN; Deutsch, M; Elefsiniotis, I; Gatselis, N; Goulis, J; Kapatais, A; Karaoulani, T; Karatapanis, S; Kranidioti, H; Kyriazidou, A; Manesis, E; Manolakopoulos, S; Mimidis, K; Mylopoulou, T; Papatheodoridi, M; Papatheodoridis, GV; Samonakis, D; Sevastianos, V; Triantos, C; Vasiliadis, T; Zisimopoulos, K | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Chen, YC; Chien, RN; Hsu, CW; Tai, DI | 1 |
| Fung, J; Huang, DQ; Kim, BK; Lim, GEH; Lim, KE; Lim, WH; Loomba, R; Muthiah, MD; Ng, CH; Nguyen, MH; Syn, N; Tamaki, N; Tan, DJH; Tang, ASP; Tay, PWL; Teng, MLP | 1 |
| Foucault, T; Gaudy-Graffin, C; Handala, L; Marlet, J; Paintaud, G | 1 |
| Fan, R; Jiang, Y; Liang, J; Liao, X; Wu, L; Yin, J; Yu, N; Zhang, Q; Zhao, S | 1 |
| Kumar, M | 1 |
| Gane, E; Kashuba, A; Levy, MT | 1 |
| Lee, MH | 1 |
| Ran, R; Wang, M; Zhang, H; Zhu, Y | 1 |
| Boyd, A; Coffie, PA; Freedberg, KA; Hyle, EP; Kim, AY; Kouamé, MG; Larmarange, J; Mohareb, AM | 1 |
| Ahn, SH; Kim, BK; Oh, J; Yoon, JH; Yun, B | 1 |
| Bai, L; Gu, J; Jia, H; Kuang, W; Lian, J; Lu, X; Lu, Y; Lv, Y; Wang, K; Yang, D; Yang, Y; Ye, C; Yu, J; Yu, Y; Zhang, J; Zhang, X; Zhang, Y; Zhao, P; Zhao, Y | 1 |
| Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M | 1 |
| Cai, H; Gao, X; Li, Z; Xie, B; Yi, N; Yi, W | 1 |
| Brakenhoff, SM; Chan, HLY; Chen, CH; Chien, RN; Choi, HSJ; Cornberg, M; Feld, JJ; Forns, X; Hansen, BE; Hirode, G; Hsu, YC; Janssen, HLA; Jeng, WJ; Kao, JH; Lens, S; Papatheodoridi, M; Papatheodoridis, GV; Seto, WK; Sonneveld, MJ; Su, TH; Van Hees, S; Vanwolleghem, T; Wong, GLH; Yuen, MF | 1 |
| Choe, WH; Kang, SH; Kim, JH; Kwon, SY; Yoo, BC; Yoon, EL | 1 |
| Chien, RN; Jeng, WJ; Liaw, YF; Liu, YC; Peng, CW; Yang, HI | 1 |
| Atalay, R; Ayrancı, FG; Çakmak, Ş; Doğanay, L; Özdil, K; Sayar, S; Tanboğa, İH | 1 |
| Lim, TO; Lim, ZZ; Tan, AC; Teo, JS | 1 |
| Papatheodoridis, GV | 2 |
| Chen, CH; Tseng, TN | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI | 1 |
| Chang, KC; Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Lu, SN; Wang, JH | 1 |
| Chen, EQ; Wang, ML | 1 |
| Ogawa, E | 2 |
| Accarino, EV; Ahn, SB; Buti, M; Chen, CH; Cheung, R; Cho, YK; Chuang, WL; Dai, CY; Enomoto, M; Gadano, A; Hoang, J; Hsu, YC; Huang, CF; Huang, D; Huang, JF; Huang, YT; Istratescu, D; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, SE; Kozuka, R; Lee, DH; Lim, SG; Lin, CH; Liu, L; Marciano, S; Nguyen, MH; Oh, H; Peng, CY; Preda, C; Riveiro-Barciela, M; Su, JY; Toyoda, H; Trinh, H; Trinh, L; Tsai, PC; Wong, GL; Wong, VW; Xie, Q; Yasuda, S; Yeh, ML; Yoon, E; Yu, ML; Yuen, MF | 1 |
| Bi, X; Deng, W; Jiang, T; Li, M; Lin, Y; Lu, Y; Sun, F; Xie, Y; Yang, L; Yi, W; Zhang, L | 1 |
| Guo, P; Qin, X; Yan, H; Yang, X; Zhang, X | 1 |
| Baek, YH; Chae, HB; Cheon, GJ; Cho, HC; Cho, YK; Chon, YE; Hwang, JS; Kang, MK; Kim, JH; Kim, SU; Koh, MS; Kweon, YO; Lee, C; Lee, JH; Lee, JS; Lim, YS; Park, NH; Park, YM; Sohn, JH; Yim, HJ | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M | 1 |
| Béguelin, C; Bernasconi, E; Boillat-Blanco, N; Calmy, A; Günthard, HF; Hofmann, E; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Suter-Riniker, F; Wandeler, G | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kimura, O; Kobayashi, T; Masamune, A; Nakamura, T; Niitsuma, H; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, T; Sawahashi, S; Takai, S; Tsuruoka, M | 1 |
| Xu, D; Yu, J | 1 |
| Adjei, G; Adu, F; Anyanful, A; Ephraim, RKD; Gavor-KWashi, C; Nsiah, P; Nyarko, SB; Thomford, NE | 1 |
| Brakenhoff, SM; de Knegt, RJ; de Man, RA; Katwaroe, WK; Sonneveld, MJ; van der Meer, AJP; van der Spek, DPC; van Kleef, LA | 1 |
| Afdhal, NH; Chan, HLY; Chen, CY; Coffin, CS; Elkhashab, M; Fung, SK; Greenbloom, S; Iyer, RP; Jackson, K; Jang, JW; Jeng, WJ; Kim, DJ; Kim, W; Kim, YJ; Lee, KS; Lim, YS; Liu, CJ; Locarnini, SA; Macfarlane, C; Ramji, A; Yuen, MF | 1 |
| Arribas, JR; Cahn, P; Daar, ES; Gibas, KM; Kelly, SG; Orkin, C; Sax, PE; Taiwo, BO | 1 |
| Afzalpurkar, S; Agrawal, D; Angadi, S; Giri, S; Gopan, A; Sundaram, S | 1 |
| Adekanle, O; Adeyemi, A; Anyabolu, C; Awowole, I; Ijadunola, M; Ijarotimi, O; Kuti, O; Makinde, O; Ndububa, D | 1 |
| Beck, A; Fichtl, A; Seufferlein, T; Zizer, E | 1 |
| Baum, MM; Kiser, JJ; Thomas, DL | 1 |
| Aeschbacher, T; Buti Ferret, M; Feierbach, B; Gaggar, A; Gane, E; Jackson, K; Janssen, HLA; Littlejohn, M; Marcellin, P; Martin, R; Meagher, N; Price, DJ; Revill, PA; Sozzi, V; Suri, V; Tan, SK; Thompson, AT; Wagner, J; Wong, D; Yuen, L | 1 |
| Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Hou, J; Li, Y; Qiang, Z; Zhang, Y | 1 |
| Cao, XY; Chen, JW; Qi, X; Zhang, JM | 1 |
| Brooks-Rooney, C; Cant, H; Chen, CH; Chen, CY; Choi, WM; Curteis, T; Huang, YH; Jin, YJ; Jun, DW; Kim, JW; Kim, WR; Lim, YS; Park, NH; Peng, CY; Shin, HP; Shin, JW; Wong, GL; Yang, YH; Yee, LJ; Yip, TC | 1 |
| Chen, T; Feng, Y; He, Y; Liu, J; Shi, L; Yao, N; Zhao, Y; Zhu, Y | 1 |
| Deng, Y; Pan, CQ; Park, J; Zhu, L | 1 |
| Belle, SH; Chung, RT; Cooper, SL; Di Bisceglie, AM; Fried, MW; Ghany, MG; Janssen, HLA; Khalili, M; Lau, DTY; Lisker-Melman, M; Lok, AS; Patel, K; Perrillo, RP; Roberts, LR; Sterling, RK; Terrault, NA; Wahed, AS; Wong, DK | 1 |
| Guo, Y; Han, J; He, J; Huang, Y; Mao, R; Sun, J; Zhang, J; Zhang, X; Zhang, Y | 1 |
| Byun, KS; Choi, J; Kim, JH; Lim, YS; Yoo, BC | 1 |
| Hu, L; Lyu, C; Shao, J; Wang, Y; Zhang, L | 1 |
| Chen, B; Jiang, L; Jin, L; Lu, H; Yang, J; Ye, P; Zhang, H | 1 |
| Chang, MH; Eom, HS; Hyun, SY; Jo, JC; Kang, HJ; Kim, DY; Kim, HJ; Kim, IH; Kim, JS; Kim, MK; Kim, WS; Kim, YR; Kwak, JY; Lee, JO; Lee, WS; Lim, SN; Mun, YC; Park, Y; Shin, HJ; Suh, C; Yang, DH; Yoo, KH; Yoon, DH | 1 |
| Gao, F; Li, C; Qi, W; Shen, J; Zhang, Y | 1 |
| Albillos, A; Amador-Navarrete, A; Arenas, JI; Badía, E; Bañares, R; Bernal-Monterde, V; Buti, M; Cabezas, J; Calleja, JL; Conde, MH; Cordero, P; Crespo, J; de Santiago, ER; Diago, M; Díaz-Fontenla, F; Fernández-Rodríguez, C; García-Buey, L; García-Retortillo, M; Garcia-Samaniego, J; Gea, F; Hoyas, E; Lens, S; Madejón, A; Mancebo, A; Marcos-Fosch, C; Mateos-Muñoz, B; Miquel, M; Moreno, JJ; Moreno, S; Morillas, RM; Pardo, A; Ramos-Merino, L; Rodríguez, M; Rodríguez-Tajes, S; Romero-Gomez, M; Santiago, JMG; Simón, MÁ; Turnes, J; Vázquez, IF | 1 |
| Cheng, H; Guo, Y; Tang, K; Wang, H | 1 |
| Chan, HL; Hui, VW; Lai, JC; Lai, MS; Liang, LY; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Nguyen, TK; Van Le, D | 1 |
| Chen, CL; Chen, PJ; Hong, CM; Kao, JH; Lin, MJ; Liou, JM; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Ahn, SB; Chen, CH; Chen, CY; Cho, YK; Choi, WM; Hur, MH; Jang, MJ; Jeong, SW; Jin, YJ; Jun, DW; Kim, HS; Kim, HY; Kim, SE; Kim, SU; Kim, YJ; Lee, HA; Lee, HC; Lee, JH; Lim, YS; Park, MK; Park, SY; Peng, CY; Seo, YS; Shim, JJ; Shin, HP; Sinn, DH; Sohn, JH; Wong, GL; Yip, TC; Yoon, EL; Yoon, JH | 1 |
| Chang, CC; Chiou, JF; Hou, MC; Huang, YH; Huo, TI; Kao, WY; Lee, HL; Su, CW; Tan, EC; Wu, JC | 1 |
| Mizokami, M; Murata, K | 1 |
| Barreiro, P; Corral, O; Mendoza, C; Moreno-Torres, V; Soriano, V | 1 |
| Chan, KM; Cheng, CH; Chou, HS; Hung, HC; Lee, CF; Lee, JC; Lee, WC; Wang, YC; Wu, TH; Wu, TJ | 1 |
| Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, SU; Lee, JI; Lee, JS | 1 |
| Hu, X; Li, Y; Luo, H; Qin, B; Tan, G | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lu, SN; Peng, CY; Wang, JH | 1 |
| Belle, SH; Ghany, MG; Janssen, HLA; Leonard, K; Lok, AS; Perrillo, R; Terrault, N | 1 |
| Cho, H; Chon, YE; Ha, Y; Hwang, SG; Kim, MN; Lee, JH; Lee, YB; Park, H; Rim, KS | 1 |
| Chuan, L; Linye, H; Tianfu, W; Xiaoyun, Z; Zhihui, L; Zijing, X | 1 |
| Arai, K; Hayakawa, N; Honda, M; Horii, R; Kagaya, T; Kaneko, S; Kawaguchi, K; Komura, T; Mizukoshi, E; Nio, K; Nishikawa, M; Orita, N; Sakai, Y; Shimakami, T; Shimode, T; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Ahn, SH; Chon, YE; Kim, BK; Kim, DY; Kim, H; Kim, SU; Lee, HW; Lee, JS; Park, JY; Park, SY; Park, T; Seo, YS | 1 |
| Cho, EJ; Jang, H; Kim, TM; Kim, YJ; Lee, HG; Lee, JH; Lee, YB; Yoon, JH; Yu, SJ | 1 |
| Cho, JY; Choi, D; Choi, Y; Hwang, S; Joo, DJ; Kang, KJ; Kim, BW; Kim, DG; Kim, DS; Kim, MS; Lee, JG; Nah, YW; Rhu, J; Ryu, JH; Yang, JD; You, YK | 1 |
| Jiang, L; Lou, Z; Pan, L; Ruan, B; Xu, X; Zeng, Y | 1 |
| Chon, YE; Ha, Y; Han, S; Hwang, SG; Kim, KM; Kim, MN; Lee, D; Lee, HC; Lee, JH; Lim, J; Shim, JH | 1 |
| Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E | 1 |
| Amin, MM; Darmadi, D; Eyanoer, PC; Lindarto, D; Lubis, M; Rey, I; Rusda, M; Siregar, J; Widyawati, T; Yusuf, F | 1 |
| Behrendt, H; Bieda, A; Leśniak, K; Niemczyk, S | 1 |
| Li, ZH; Liu, ZX; Luo, JX; Su, JY; Wang, YY; Wu, KJ; Wu, XL; Wu, YL; Zhong, JH | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Grude, S; Gundersen, SG; Hommersand, K; Johannessen, A; Mamo, E; Orlien, SMS | 1 |
| Choi, J; Choi, WM; Lim, YS | 2 |
| Evon, DM; Fontana, RJ; Hoofnagle, JH; Khalili, M; Lin, HS; Wahed, AS; Yim, C | 1 |
| Abdullah, T; Aydin, O; Çolak, M; Kinaci, E; Ocak, İ; Özcan, FG; Özden, İ; Poturoğlu, Ş | 1 |
| Aladag, M; Yakut, A | 1 |
| Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z | 1 |
| He, S; Wang, L; Wang, N; Zheng, Y | 1 |
| Duan, YQ; Hu, P | 1 |
| Fan, R; Fan, Y; Guo, L; Liao, X; Tan, W; Yin, J; Zhao, S; Zhong, C | 1 |
| Li, C; Peng, W; Qi, W; Qi, X; Wen, T; Yi, M | 1 |
| Chen, R; Huang, B; Li, Q; Li, X; Lin, S; Liu, L; Liu, Y; Luo, D; Niu, M; Wang, J; Xu, D | 1 |
| Chen, XY; Cheng, J; Dai, J; Gao, ZL; Li, J; Liang, RY; Mao, Q; Shang, J; Si, CW; Tang, H; Wang, H; Wang, L; Wang, S; Wu, SM; Xie, Q; Xu, JH; Xu, ZN; Yu, YY; Yu, ZJ; Zhang, WH; Zhao, W | 1 |
| Chen, MB; Ding, YL; Fan, JN; Wang, H; Yue, MX; Zheng, QH; Zheng, XW | 1 |
| Koh, YH; McCartney, E; Morgan, J; Narayana, S; Ong, JHY; Tse, E | 1 |
| Chang, KC; Chang, MH; Chen, HL; Lin, LH | 1 |
| Han, Z; Hou, H | 1 |
| Jiang, D; Li, Y; Song, C; Wang, J; Wang, X; Zeng, H; Zhang, Q; Zhao, X | 1 |
| Chan, HL; Chan, SL; Choi, J; Le, A; Lim, YS; Liu, K; Nguyen, MH; Wong, GL; Wong, VW; Yip, TC | 1 |
| Kimura, A; Mizokami, M; Murata, K; Noguchi, M; Sugiyama, M; Suizu, F; Tsukuda, S; Watashi, K | 1 |
| Choe, WH; Choi, YM; Kim, BJ; Kim, JH; Kim, K; Kwon, SY; Lee, SY | 1 |
| Liaw, YF | 2 |
| Blackard, JT; Kwara, A; Sherman, KE | 1 |
| Cui, FQ; Hou, JL; Jia, JD; Liu, J; Liu, YY; Liu, ZH; Tao, LB; Xie, L; Yin, XR; Zhuang, GH | 1 |
| Chan, HL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lu, SN; Ma, TL; Wang, JH | 1 |
| Kim, KH; Lee, JH | 1 |
| Benhong, Z; Jiexin, L; Peng, C | 1 |
| Chen, EQ; Liao, J; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Zhang, DM | 2 |
| Lin, L; Liu, L; Lu, J; Shen, H; Xue, Y; Zhang, H; Zhang, X; Zheng, S | 1 |
| Chen, CH; Cheung, KS; Eguchi, Y; Enomoto, M; Furusyo, N; Hoang, J; Hsu, YC; Huang, CF; Huang, R; Huang, YT; Jang, TY; Kozuka, R; Kumada, T; Lee, DH; Li, J; Liu, C; Liu, L; Nguyen, MH; Ogawa, E; Peng, CY; Takahashi, H; Tanaka, Y; Toyoda, H; Trinh, H; Tsai, PC; Wong, C; Wong, GL; Wu, C; Xie, Q; Yang, HI; Yasuda, S; Yeh, ML; Yu, ML; Yuen, MF; Zhang, JQ; Zhao, C | 1 |
| Janjua, NZ; Krajden, M; Samji, H; Wilton, J; Yu, A | 1 |
| Ahn, SH; Ferrari, C; Gish, RG; Given, BD; Hamilton, J; Heo, J; Kim, JH; Klinker, H; Lai, CL; Lik Yuen Chan, H; Locarnini, SA; Manns, M; Petersen, J; Schiefke, I; Schluep, T; Yoon, JH; Yoon, KT; Yuen, MF | 1 |
| Bae, SH; Choi, JY; Han, NI; Jang, JW; Kwon, JH; Lee, HL; Lee, SW; Nam, HC; Nam, SW; Sung, PS; Yoo, SH; Yoon, SK | 1 |
| Alsabbagh, MW; Houle, SKD; Tian, F; Wong, WWL | 1 |
| Agarwal, K; Carey, I; Cloherty, G; Dusheiko, G; Gersch, J; Kuhns, M; Moigboi, C; Wang, B | 1 |
| Liang, B; Zheng, X | 1 |
| Lampertico, P; Papatheodoridis, GV | 2 |
| Kim, BK | 2 |
| Gao, J; Yu, Y; Zhang, B; Zhang, J | 1 |
| Chen, MB; Ding, YL; Fan, JN; Niu, JL; Wang, H; Zheng, QH; Zheng, XW | 1 |
| Lee, HW | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H | 1 |
| Jiang, D; Wang, X; Zeng, H | 1 |
| Zhang, D; Zhang, Q; Zhu, F | 1 |
| Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X | 1 |
| Li, MJ; Teng, YX; Xiang, BD; Zhong, JH | 1 |
| Arslan, F; Vahaboglu, H | 1 |
| Han, BH; Jeong, J; Lee, D; Lee, JW; Lee, SU; Park, ET; Seo, KI; Yun, BC | 1 |
| Khamrin, P; Kumthip, K; Malasao, R; Maneekarn, N; Sirilert, S; Tongsong, T | 1 |
| Chan, HL; Hui, VW; Lee, HW; Liang, LY; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chan, AC; Cheung, TT; Chok, KS; Dai, WC; Fung, J; Lai, CL; Lo, CM; Ma, KW; Mak, LY; Seto, WK; She, WH; Sin, SL; Wong, TC; Yuen, MF | 1 |
| Bak, H; Byun, KS; Chang, SW; Hyun, MH; Jung, YK; Kim, JH; Kim, S; Lee, CU; Lee, HS; Lee, MJ; Lee, YS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ | 1 |
| Li, RH; Yuan, BH; Zhu, YK | 1 |
| Wong, GL; Yip, TC | 2 |
| Choi, J; Han, S; Kim, GA; Lim, YS | 1 |
| Cai, H; Duan, X; Fu, D; Gao, X; Hu, Y; Kang, K; Liu, M; Yi, W; Zhou, M | 1 |
| Chow, SC; Jia, J; Kong, Y; Li, M; Lv, T; Ma, H; Ou, X; Wei, W; Wu, S; Wu, X; You, H | 1 |
| Hsu, YC; Nguyen, MH | 1 |
| Chung, RT; Holmes, JA | 1 |
| Amano-Teranishi, Y; Enomoto, M; Kawada, N; Kawasaki, Y; Kioka, K; Nakai, T; Suoh, M; Tamori, A | 1 |
| Boyd, A; Chas, J; Delaugerre, C; Dezanet, LNC; Gabassi, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Maylin, S; Miailhes, P; Rougier, H | 1 |
| Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskin, O; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Voulgaris, T; Yurdaydin, C | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, EJ; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Seo, YS; Shin, HJ; Tak, WY; Um, SH | 1 |
| Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yamashita, K; Yasui, Y | 1 |
| Babudieri, S; Bagella, P; Bandiera, F; Calvisi, DF; Fiore, V; Garrucciu, G; Madeddu, G; Mannu, F; Melis, M; Muredda, AA; Ortu, S; Zaru, S | 1 |
| Yalaki, S; Yalcin, MS | 1 |
| Ahn, SH; Chan, HL; Lee, HW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Ahmed, A; Kamal, F; Khan, MA; Nair, S | 1 |
| Arslan, K; Ataman Hatipoğlu, Ç; Çerçioğlu, D; Cesur, S; Gönültaş, M; Kınıklı, S | 1 |
| Chen, F; Fu, X; Gao, X; Lin, Z; Lou, H | 1 |
| Chaung, KT; Cheung, R; Henry, L; Hoang, JK; Le, AK; Li, J; Nguyen, MH | 1 |
| Mak, LY | 1 |
| Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK | 1 |
| Ergen, P; Yilmaz Karadağ, F | 1 |
| Ahn, SB; Cho, YK; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, SE; Lee, HY; Oh, H; Shim, JJ; Sohn, JH; Yoon, EL | 1 |
| Bazinet, M; Cebotarescu, V; Cojuhari, L; Dittmer, U; Iarovoi, L; Jimbei, P; Jucov, A; Krawczyk, A; Moscalu, I; Musteata, T; Pântea, V; Placinta, G; Smesnoi, V; Vaillant, A | 1 |
| Gül, S; Köse, Ş; Pala, E; Tatar, B | 1 |
| Chung, JW; Ha, I; Jang, ES; Jeong, SH; Kim, JW | 1 |
| Chen, B; Chen, P; Gu, L; He, Y; Mao, F; Ng, DM; Shen, Z; Yang, T; Yao, Q; Yu, Q | 1 |
| Kim, SU; Lee, HA; Seo, YS | 1 |
| Kamal, F; Khan, MA | 1 |
| Ahn, SH; Baek, YH; Chang, Y; Choe, WH; Jang, JW; Jang, JY; Kim, GA; Kim, HY; Kim, JH; Kim, M; Kim, MA; Kim, SG; Kim, SU; Kim, YJ; Kim, YS; Koh, M; Kwon, JH; Lee, HA; Lee, HW; Lee, JH; Lee, SW; Lee, YS; Lim, YS; Park, Y; Seo, YS; Shim, JJ; Sinn, DH; Yang, H; Yim, HJ; Yoon, JH; Zoulim, F | 1 |
| Bai, X; Chen, X; Fan, R; Hou, J; Niu, J; Peng, J; Ren, H; Sheng, J; Sun, J; Tan, D; Tang, H; Wang, H; Wang, M; Wu, Y; Xie, Q; Xu, M; Zhou, B | 1 |
| Berry, K; Ioannou, GN; Su, F | 1 |
| Adams, LA; Barnard, A; Dave, S; Loomba, R; Murad, MH; Park, S; Prokop, L; Singh, S | 1 |
| Kumada, T; Miyake, N; Tada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Joo, DJ; Kim, DG; Kim, MS; Kim, SI; Lee, J; Lee, JG; Lee, JY; Park, JY; Yang, SJ | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Chang, HY; Kim, S; Lee, HW; Lee, JI; Lee, KS | 1 |
| Choi, J; Jo, C; Lim, YS | 1 |
| Bao, H; Chen, Y; Geng, J; Shi, L; Wang, Q; Yu, H | 1 |
| El-Serag, HB; Hsu, YC; Tseng, CH; Tseng, CM; Wu, JL | 1 |
| Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Wang, JH | 1 |
| Ahn, SH; Cho, YK; Han, KH; Hong, GY; Jang, JY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chang, KK; Kuo, MJ; Lin, RC; Tseng, YT; Wang, CH; Yang, CC | 1 |
| Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Kuo, YH; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Shu, YF; Xu, L; Xu, XF; Yang, W | 1 |
| Ahn, SH; Han, KH; Jeon, MY; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Lee, JS; Park, JY | 1 |
| Chang, KC; Hu, TH; Lin, MT; Tsai, MC; Wu, CK; Yen, YH | 1 |
| Cheong, JY; Chung, WJ; Jang, BK; Jang, JY; Jeong, SW; Kim, IH; Kim, SG; Kim, SS; Kim, SU; Kim, YS; Lee, BS; Lee, CH; Lee, HA; Lee, HW; Lee, JI; Lee, JW; Lim, TS; Park, SY; Rou, WS; Seo, YS; Suh, SJ; Tak, WY; Yim, HJ; Yu, JH | 1 |
| Chang, WY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, FW; Chiu, YC; Hsu, YC; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC; Yang, SS | 1 |
| Ahn, SH; Bae, SH; Heo, J; Jang, JY; Kim, CW; Kim, DJ; Kim, IH; Park, JY; Tak, WY; Woo, HY | 1 |
| Berg, T; Buti, M; Calleja, JL; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Yurdaydin, C | 1 |
| Ahn, SH; Chon, YE; Ha, Y; Han, KH; Hwang, SG; Jung, KS; Kim, DY; Kim, MN; Lee, JH; Park, JY | 1 |
| Berg, T; Botros, I; Buti, M; Flaherty, JF; Jump, B; Lampertico, P; Op den Brouw, ML; Pathil, A; Petersen, J; Ramroth, H; Ryder, SD; van Troostenburg, A; Zoulim, F | 1 |
| Kim, BK; Kim, SU | 1 |
| Cheng, M; Feng, X; Ma, L; Wang, B; Wang, L; Yang, Y | 1 |
| Jang, BK | 1 |
| Andersson, M; Barnes, E; Bonsall, D; de Cesare, M; Gabriel, S; Hugo, S; Maponga, TG; Matthews, PC; McNaughton, AL; Mokaya, J; Preiser, W; Singer, JB; Sreenu, VB; Taljaard, J; Van Rensburg, C; Van Schalkwyk, M | 1 |
| Alam, A; Charlton, MR; Cua, IHY; Dashtseren, B; Duger, D; Duy Cuong, D; Gani, RA; Hashmi, ZY; Hien, PTD; Jargalsaikhan, G; Kyi, KP; Lesmana, CRA; Madan, K; Mohamed, R; Naing, W; Payawal, DA; Piratvisuth, T; Rastogi, M; Salih, M; Saraf, N; Shukla, A; Singh, KR; Sollano, JD; Sukeepaisarnjaroen, W; Tanwandee, T; Thuy, PTT; Tun, KS; Win, KM | 1 |
| Chayama, K; Enomoto, H; Enomoto, M; Hiramatsu, N; Ikeda, F; Ito, K; Kagawa, T; Kanda, T; Kang, JH; Kondo, Y; Masaki, T; Matsui, T; Matsumoto, A; Miyase, S; Morihara, D; Murata, K; Nagaoka, S; Nishiguchi, S; Okuse, C; Saito, S; Shinkai, N; Takaguchi, K; Tanaka, E; Tanaka, Y; Tsuge, M; Yamada, R; Yatsuhashi, H | 1 |
| Audsley, J; Avihingsanon, A; Bowden, S; Fairley, CK; Lewin, SR; Littlejohn, M; Matthews, GV; Sasadeusz, J | 1 |
| Borghi, M; Buti, M; di Paolo, D; Esteban, R; Facchetti, F; Lampertico, P; Loglio, A; Lunghi, G; Riveiro-Barciela, M; Roade, L; Soffredini, R; Tabernero, D | 1 |
| Hwang, SG; Jang, JY; Jung, YK; Kim, HS; Kim, IH; Kim, JH; Kim, YS; Lee, SH; Lee, YS; Park, JY; Seo, YS; Song, MJ; Suh, SJ; Um, SH; Yim, HJ; Yoon, EL | 1 |
| Eminler, AT; Koksal, AS; Parlak, E; Toka, B; Tozlu, M; Uslan, MI | 1 |
| Anugwom, CM; Bane, A; Braimoh, GA; Debes, JD; Sultan, A; Wondifraw, Z | 1 |
| Agah, S; Bagheri-Hosseinabadi, Z; Bahardoust, M; Barati, M; Karimi Behnagh, A; Keyvani, H; Mokhtare, M | 1 |
| Ge, Z; Gou, W; Ma, J; Qiao, B; Wang, Y; Zhang, H | 1 |
| Chon, YE; Ha, Y; Hwang, SG; Kim, MN; Lee, JH | 1 |
| Boucheron, P; Bulterys, M; Chou, R; Funk, AL; Lu, Y; Shimakawa, Y; van Holten, J; Yoshida, K; Zhao, T | 1 |
| Bin, W; Jianfei, L; Jiming, Z; Ling, L; Yu, Z | 1 |
| Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L | 1 |
| Kim, SU; Lee, SW | 1 |
| Chen, J; Wang, Y; Wu, J | 1 |
| Chen, EQ; Tao, YC | 1 |
| Hall, S; Howell, J; Thompson, A; Visvanathan, K | 1 |
| Con, D; Goodwin, T; Kemp, W; Majeed, A; Roberts, S | 1 |
| Feld, JJ; Fung, S; Hansen, BE; Janssen, HLA; Liem, KS; Wong, DK; Yim, C; Zahirieh, A; Zanjir, WR | 1 |
| Angkurawaranon, C; Bierhoff, M; Carrara, V; Ehrhardt, S; Guo, N; Jia, Y; Jittamala, P; Ling, C; McGready, R; Nelson, KE; Nosten, F; Rijken, M; Thio, CL; Tongprasert, F; van Vugt, M; Watthanaworawit, W | 1 |
| Flomo, KT; Ma, Y; Yang, Q; Yang, Y; Zhong, Z | 1 |
| Lampertico, P; Papatheodoridis, G; Sypsa, V | 1 |
| Danta, M; Dore, GJ; Matthews, GV | 1 |
| Borghi, JA; Chen, IS; Chen, TH; Cheung, R; Enomoto, M; Hai, H; Hosaka, T; Hsu, YC; Ji, F; Nguyen, MH; Sezaki, H; Thuy, LTT; Tsai, YN; Tseng, CH | 1 |
| Feng, Y; Wen, Z; Yan, X | 1 |
| He, S; Xie, X; Yao, J; Yu, J; Yuan, G | 1 |
| Ahn, SH; Chang, JW; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, JS; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Cheng, HM; Cheung, KS; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Yuen, MF | 1 |
| Chainuvati, S; Chotiyaputta, W; Kiattisunthorn, K; Poosanasuwansri, K; Tanwandee, T | 1 |
| Aspinall, AI; Barkema, HW; Borman, MA; Burak, KW; Castillo, E; Coffin, CS; Congly, SE; Israelson, H; Lee, SS; Martin, SR; Pinto, J; Sadler, MD; Samadi Kochaksaraei, G; Seow, CH; Shaheen, AA; Stinton, LM; Swain, MG; Williams, S | 1 |
| Chang, KC; Chen, CH; Chien, RN; Hu, TH; Hung, CH; Kee, KM; Lin, MC; Lin, MT; Lu, SN; Tseng, PL; Wang, JH; Yueh-Hsia Chiu, S | 1 |
| Abdel Alem, S; Atef, M; Hamed, M; Saber, M; Salama, R; Yosry, A; Yousof, H; Zayed, N | 1 |
| Abraham, P; Isaac, B; Ramamoorthy, H | 1 |
| Cloherty, G; Fung, J; Gersch, J; Mak, LY; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Ostankova, YV; Semenov, AV; Serikova, EN; Totolian, AA; Zueva, EB | 1 |
| Liu, Y; Mo, Y; Wu, A | 1 |
| Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
| Daugherty, T; Goel, A; Kim, WR; Kwo, PY; Kwong, A; Mannalithara, A; Sripongpun, P | 1 |
| Chang, JW; Kim, SU | 1 |
| Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF | 1 |
| Chen, G; Chen, SH; Fu, YM; Ji, D; Li, L; Li, ZB; Liu, Y; Niu, XX; Shao, Q; Wang, CY | 1 |
| Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X | 1 |
| Choi, J; Choi, WM; Han, S; Lim, YS; Wong, GL | 1 |
| Hsu, YC; Nguyen, MH; Tseng, CH | 1 |
| Chang, TS; Chen, WM; Hsieh, YY; Hung, CH; Lee, CP; Lu, SN; Shen, CH; Tsai, ML; Tung, SY; Yang, YH; Yen, CW | 1 |
| Pol, S | 1 |
| Ahn, SH; Cho, YK; Han, KH; Hong, GY; Jang, JY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, SJ; Sohn, JH; Song, DS; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Hu, C; Li, M; Liao, M; Liu, J; Song, Y; Tang, C; Zhang, YY; Zhou, F; Zhou, Y | 1 |
| Chan, HL | 1 |
| Bair, MJ; Chang, CY; Chang, IW; Chen, CC; Chen, CY; Chen, JJ; Hsu, YC; Huang, YT; Ku, WH; Lee, TY; Lin, JT; Mo, LR; Tai, CM; Tseng, CH; Wu, CY; Wu, MS | 1 |
| Ahn, CH; Cho, JY; Choo, SY; Dezhbord, M; Kim, DS; Kim, JC; Kim, KH; Kim, NY; Lee, AR; Lee, JH; Park, ES; Park, S; Shin, JJ; Won, J | 1 |
| Carrat, F; Fontaine, H; Luzivika Nzinga, C; Pol, S | 1 |
| Chen, R; Li, J; Li, L; Li, X; Liu, LM; Liu, Y; Shao, J; Xu, D; Zhao, L; Zhou, Y | 1 |
| Boglione, L; Cariti, G; Cusato, J; De Benedetto, I; Di Perri, G; Lupia, T | 1 |
| Adalı, G; Bahadır, Ö; Can, G; Değirmenci Saltürk, AG; Doğanay, HL; Gökçen, P; Güzelbulut, F; Özdil, K | 1 |
| Hao, FB; Peng, Y; Wang, CR; Wang, YQ; Yuan, J; Zhong, GC | 1 |
| Jain, MK; Kshirsagar, O; Niu, B; Thamer, M; Therapondos, G; Wong, RJ | 1 |
| Tseng, TC | 1 |
| Arai, T; Asai, A; Atsukawa, M; Cheung, R; Chien, N; Chuma, M; Dang, H; Fukunishi, S; Henry, L; Hoang, J; Huang, DQ; Ishikawa, T; Landis, C; Le, RH; Leong, J; Lim, SG; Liu, J; Maeda, M; Nguyen, MH; Quek, SXZ; Senoo, T; Takaguchi, K; Thin, KN; Toyoda, H; Tran, S; Trinh, HN; Uojima, H; Watanabe, T; Yasuda, S; Yokohama, K | 1 |
| Bai, L; Liu, H; M Ise, R; Shang, J; Tang, H; Tu, Y; Wen, Q | 1 |
| Bhan, AK; Chung, RT; Ghany, MG; Hinerman, AS; Jain, MK; Khalili, M; King, WC; Kleiner, DE; Lisker-Melman, M; Sterling, RK; Sulkowski, M; Wahed, AS; Wong, DK | 1 |
| Brahmania, M; Coffin, CS; Conway, B; Cooper, C; Doucette, K; Farag, MS; Fung, S; Hansen, BE; Haylock-Jacobs, S; Janssen, HLA; Ramji, A; Sebastiani, G; Tam, E; Tsoi, K; Wong, A; Wong, P | 1 |
| Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chen, X; Chen, Y; Dai, E; Duan, Z; Han, G; Jiang, H; Pan, CQ; Wang, Y; Zhang, H; Zhang, S; Zhang, X; Zhao, W; Zhu, B; Zou, H | 1 |
| Ahn, SH; Kim, BK; Kim, DY; Kim, SU; Lee, JH; Park, JY; Park, SY; Sinn, DH; Tak, WY | 1 |
| Gedik, H; Sonmezisik, M | 1 |
| Carrat, F; Lusivika Nzinga, C; Pol, S | 1 |
| Huang, R; Liu, J; Wang, J; Wu, C | 1 |
| Chen, R; Wang, JG; Wang, LC | 1 |
| Chang, KC; Chien, RN; Chiu, SY; Hu, TH | 1 |
| Choi, H; Seo, GH | 1 |
| Cho, Y; Jeong, S; Kim, W; Park, SM | 1 |
| Cho, S; Kim, GA; Kim, HJ; Ko, MJ; Lee, J; Lim, YS | 1 |
| Dubey, G; Jindal, A; Vyas, A | 1 |
| Byun, KS; Choi, J; Gwak, GY; Kim, JH; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 1 |
| Bae, SH; Brunetto, M; Çelen, MK; Chang, TT; Coffin, CS; Flaherty, JF; Gaggar, A; Gane, EJ; Mo, S; Nguyen, MH; Pan, CQ; Seto, WK; Tan, SK; Thompson, A | 1 |
| de Carvalho Santana, R; de Lourdes Candolo Martinelli, A; Dessordi, R; Guimarães, MP; Navarro, AM; Romão, EA; Watanabe, LM | 1 |
| Accarino, EV; Buti, M; Chen, CH; Cheung, KS; Cheung, R; Chuang, WL; Dai, CY; Enomoto, M; Hoang, J; Hsu, YC; Huang, CF; Huang, JF; Istratescu, D; Kozuka, R; Lee, DH; Liu, L; Nguyen, MH; Peng, CY; Preda, C; Riveiro-Barciela, M; Trinh, H; Tsai, PC; Wong, GL; Wong, VW; Wu, JL; Xie, Q; Yeh, ML; Yeo, YH; Yu, ML; Yuen, MF | 1 |
| Bhardwaj, N; Combet, C; Gaggar, A; Hedskog, C; Mo, H; Murray, KF; Podlaha, O; Svarovskaia, E; Zoulim, F | 1 |
| Sonneveld, MJ; van Erpecum, KJ | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU | 1 |
| Iatan, I; Lee, TC; McDonald, EG | 1 |
| Abid, H; Abkari, ME; Adil, N; Aqodad, N; M'bodj, K | 1 |
| Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC | 1 |
| Arai, T; Atsukawa, M; Cheung, R; Chuma, M; Dang, H; Enomoto, M; Fukunishi, S; Hsu, YC; Ishikawa, T; Jun, DW; Kawada, N; Maeda, M; Nguyen, MH; Nozaki, A; Ogawa, E; Takaguchi, K; Takahashi, H; Toyoda, H; Trinh, HN; Tseng, CH; Watanabe, T; Yasuda, S; Yokohama, K | 1 |
| Chen, XB; Liu, FF; Liu, JY; Shu, FL; Yang, JH | 1 |
| Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M | 1 |
| Buti, M; Esteban, R; Marcos-Fosch, C | 1 |
| Choi, J; Kim, SU; Lee, SW; Lim, YS | 1 |
| Choe, WH; Kim, JH; Kwon, SY; Na, JH; Yoo, BC | 1 |
| Chien, RN; Jeng, WJ; Liaw, YF | 1 |
| Hsu, YC; Huang, YT; Lin, JT | 1 |
| Barnes, E; Campbell, C; Collier, J; Cripps, S; Davies, J; Freeman, O; Jeffery, K; Matthews, PC; McNaughton, AL; Mokaya, J; Noble, T; Salih, H; Smith, DA; Várnai, KA; Wang, T; Woods, K | 1 |
| Dai, Z; Lau, EHY; Peng, L; Wong, IOL; Xiang, Y; Xie, C; Xu, W | 1 |
| Chen, J; Chen, L; Gao, Y; Gong, Q; Han, Y; Jiang, J; Li, J; Liu, Y; Qu, L; She, W; Sun, X; Wei, D; Yu, D; Zhang, D; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Adalı, G; Aslan, E; Can, G; Değirmenci Saltürk, AG; Doğanay, HL; Gökçen, P; Güzelbulut, F; Özdil, K | 1 |
| Chen, CH; Fang, HW; Hu, TH; Hung, CH; Lu, SN; Wang, JH; Yen, YH | 1 |
| Baek, SY; Choi, MS; Gwak, GY; Jang, HJ; Kang, WS; Kim, KA; Kim, YJ; Koh, KC; Lee, JH; Na, JE; Paik, SW; Paik, YH; Sinn, DH; Yoon, JH | 1 |
| Busca Arenzana, C; Daroca, G; Martin-Carbonero, L; Mican, R; Perez-Valero, I; Vasquez, J | 1 |
| Balkan, II; Erturk, US; Guney, B; Kacmaz, B; Mert, A; Mete, B; Ozaras, R; Saglam, O; Saltoglu, N; Sayman, OA; Tabak, F | 1 |
| Duan, M; Gu, Y; Li, B; Liu, D; Liu, Q; Liu, X; Liu, Z; Ma, Q; Wang, Y; Wei, Y | 1 |
| Chen, G; Gu, D; Huang, R; Jia, B; Liu, J; Liu, Y; Wang, J; Wu, C; Xiang, X; Yan, X; Yang, Y; Zhang, Z; Zhao, XA | 1 |
| Li, EM; Li, JQ; Lin, CS; Mei, YY; Mo, ZS; Xiao, LX; Xu, Z | 1 |
| Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY | 2 |
| Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ | 1 |
| Capobianchi, MR; D'Offizi, G; Menzo, S; Piselli, P; Solmone, M; Vincenti, D | 1 |
| Arends, P; Chen, L; Chi, H; de Knegt, RJ; Guo, Q; Guo, S; Hansen, BE; Janssen, HLA; Qi, X; Verhey, E; Wang, JY; Xie, Q; Zhang, NP | 1 |
| Cho, H; Kang, H; Lee, HH | 1 |
| An, J; Byun, KS; Choi, J; Gwak, GY; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 1 |
| Celià-Terrassa, T; Gregori, J; Kang, Y; Luedde, T; Ploss, A; Rodríguez-Frías, F; Shirvani-Dastgerdi, E; Tabernero, D; Tacke, F; Trautwein, C; Winer, BY; Yagmur, E | 1 |
| He, L; Jiang, Y; Liu, X; Wang, X; Yang, Z; Zhang, S; Zhao, Y | 1 |
| Huang, JR; Lian, JS; Liu, YY; Pan, LF; Yang, JL; Zhou, J | 1 |
| Karris, MY | 1 |
| Brouwer, WP | 1 |
| Acharya, SK; Agarwal, K; Chan, HL; Chen, CY; Chowdhury, A; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Gane, E; Hui, AJ; Janssen, HL; Kim, HJ; Kitrinos, KM; Lim, YS; Lin, L; Massetto, B; McHutchison, JG; Mehta, R; Seto, WK; Subramanian, GM; Tsang, TY | 1 |
| Acharya, SK; Brunetto, M; Buti, M; Cathcart, AL; Chan, HL; Chuang, WL; Flaherty, JF; Gaggar, A; Gane, E; Hui, AJ; Izumi, N; Janssen, HL; Kim, K; Lim, YS; Marcellin, P; Massetto, B; McHutchison, JG; Mehta, R; Pan, CQ; Seto, WK; Stepanova, T; Subramanian, GM | 1 |
| Perricone, G; Pungolino, E; Vinci, M | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Park, JY; Rim, KS | 1 |
| Chamroonkul, N; Piratvisuth, T | 1 |
| Cheon, GJ; Don Kim, Y; Jang, JY; Jeong, SW; Jun, BG; Jun, DW; Kim, BS; Kim, HS; Kim, SG; Kim, TY; Kim, YS; Lee, BS; Lee, SH; Sohn, JH | 1 |
| Byun, KS; Hyun, MH; Je, JH; Kim, JH; Lee, YS; Yeon, JE; Yoo, YJ | 1 |
| Abdul Basit, S; Dawood, A; Gish, R; Ryan, J | 1 |
| Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, HA; Seo, HY; Wang, JH | 1 |
| Chan, HLY; Scott, LJ | 1 |
| Liu, CJ; Su, TH | 1 |
| Abdul Hafidz, MI; Lee, YY; Tan, SS | 1 |
| Hu, C; Huang, H; Li, Y; Liu, J; Yang, D; Yuan, G; Zhang, YY; Zhou, F; Zhou, Y | 1 |
| Beuers, U; de Niet, A; Jansen, L; Koot, M; Kuiken, SD; Molenkamp, R; Reesink, HW; Stelma, F; Takkenberg, RB; van Nieuwkerk, CMJ; Verheij, J; Weijer, S; Willemse, SB; Zaaijer, HL | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, GN; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Stene-Johansen, K | 1 |
| Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, J; Park, JY | 1 |
| Heo, NY | 1 |
| Ahn, JS; Jeon, HJ; Jung, SW; Kim, HR; Lee, JH; Noh, JH; Park, NH; Shin, JW; Yang, Y | 1 |
| Cho, HJ; Yoo, EH | 1 |
| AlMattooq, M; Borman, MA; Burak, KW; Coffin, CS; Congly, SE; Lee, SS; Myers, RP; Shaheen, AA; Swain, MG; Yazdanfar, S | 1 |
| Chan, HL; Chan, RS; Chim, AM; Hui, AJ; Lo, AO; Wong, GL; Wong, VW | 1 |
| Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G | 1 |
| Akinci, E; Alpat, SN; Ari, A; Gunal, O; Guner, R; Kayaaslan, B; Tabak, F; Tosun, S; Tufan, ZK | 1 |
| Byun, KS; Hyun, MH; Kim, JH; Lee, YS; Yeon, JE | 1 |
| Ahir, BK; Li, LQ; Wu, GB; Zhang, CY; Zhong, JH | 1 |
| Chen, J; Huang, Y; Huang, ZB; Liu, XX; Zhao, SS | 1 |
| Bang, SJ; Du Jeong, I; Jung, SW; Kim, BG; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW | 1 |
| Al-Mattooq, M; Borman, MA; Burak, KW; Coffin, CS; Congly, SE; Lee, SS; Myers, RP; Shaheen, AA; Swain, MG; Yazdanfar, S | 1 |
| Huang, R; Wang, J; Wu, C; Xia, J; Yan, X | 1 |
| Cathcart, AL; Delaney, WE; Kitrinos, KM; Liu, Y | 1 |
| Lee, JH; Lee, YB | 1 |
| Hsu, YC; Nguyen, MH; Wei, MT | 1 |
| Ferrara, SM; Santantonio, T; Sica, S; Tartaglia, A | 1 |
| Chen, S; Huang, J; Huang, Y; Li, G; Qiu, C; Shen, C; Wang, B; Wang, J; Wang, X; Yu, Y; Zhang, J; Zhang, W; Zhao, C | 1 |
| Wang, Y; Zhao, LF | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Song, JE | 1 |
| Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY | 1 |
| Antinori, S; Binda, F; Cannizzo, ES; Cazzaniga, FA; d'Arminio Monforte, A; Marchetti, G; Milazzo, L; Ronzi, P; Tincati, C | 1 |
| Cho, JH; Choi, SW; Chun, DI; Kwon, SH; Lee, HW; Nho, JH; Suh, YS; Won, SH | 1 |
| Blanco, MÁ; Bonet, ML; Calleja, JL; Casado, MÁ; Fraga, E; Fuentes, J; García-Buey, ML; González, JM; Jorquera, F; Molina, E; Pascasio, JM; Pons, JA; Prieto, M; Rodríguez, M; Salmerón, J; Sánchez-Antolín, G | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 2 |
| Furusyo, N; Nguyen, MH; Ogawa, E | 1 |
| Jang, JW; Kim, H; Kim, YH; Kwon, JH; Lee, JY; Nam, SW | 1 |
| El-Serag, HB; Ho, HJ; Hsu, YC; Huang, YT; Lee, TY; Lin, JT; Wu, CY; Wu, MS | 1 |
| Choe, BH; Choe, JY; Kang, B; Kim, JE; Ko, JS; Lee, KJ; Yang, HR | 1 |
| Chen, CH; Hsu, YC; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Iio, E; Inoue, T; Kumada, T; Matsunami, K; Murakami, S; Nojima, M; Ogawa, S; Shinkai, N; Tanaka, Y; Toyoda, H | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Kao, JH; Liou, JM; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Becht, E; Bertoletti, A; Cheng, Y; Foster, GR; Gill, US; Hansi, NK; Kao, JH; Kennedy, PT; Kunasegaran, K; Le Bert, N; Lim, SG; Newell, EW; Rivino, L; Su, TH; Tan, DZ; Tseng, TC | 1 |
| Angeli, P; Fasolato, S; Gambino, C; Mareso, S; Piano, S; Pilutti, C; Pontisso, P; Romano, A; Sartori, L; Stanco, M; Tonon, M | 1 |
| Ahn, H; Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jung, YJ; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Grossi, G; Lampertico, P; Loglio, A; Viganò, M | 2 |
| Buti-Ferret, M; Edwards, R; Gaggar, A; Gane, E; Jackson, K; Janssen, H; Kitrinos, K; Littlejohn, M; Locarnini, S; Marcellin, P; Revill, P; Subramanian, M; Thompson, A; Wong, D | 1 |
| Gadano, A; Marciano, S | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Baymbajav, B; Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Jung, WJ; Kim, BS; Kim, HS; Kim, SG; Kim, YS; Lee, HJ; Lee, SH; Park, S; Park, SJ; Park, WY | 1 |
| Chang, KC; Chen, CH; Chou, YP; Hu, TH; Hung, CH; Kuo, MT; Kuo, YH; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH | 1 |
| El-Serag, HB; Ho, HJ; Hsu, YC; Huang, YT; Lee, TY; Lin, JT; Wong, GL; Wong, VW; Wu, CY; Wu, MS; Yip, TC | 1 |
| Dickson, I | 1 |
| Hu, YK; Huang, YX; Jin, JL; Ying, Y; Zhang, JM; Zhang, WH | 1 |
| Kang, MK; Park, JG | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY; Yang, JH | 1 |
| Brahmania, M; Gomes, T; Janssen, HLA; Juurlink, DN; Knowles, S; Mamdani, MM; Martins, D; Tadrous, M | 1 |
| Chen, YL; Dai, L; Li, QH; Lin, JZ; Ma, JD; Mo, YQ; Wang, XY; Yan, T; Yang, ZH; Zheng, DH | 1 |
| Chan, HL; Lam, KL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 2 |
| Agarwal, K; Ahn, SH; Andreone, P; Bulusu, A; Cathcart, AL; Chuang, WL; Elkhashab, M; Gaggar, A; Kim, HJ; Lau, AH; Nguyen, MH; Subramanian, GM; Tian, X; Woo, J | 1 |
| Calinas, F; Costa, MN; Germano, I; Loureiro, RV | 1 |
| Cornberg, M; Crabé, S; Gineste, P; Höner Zu Siederdissen, C; Hui, AJ; Manns, MP; Nieto, GEG; Nitcheu, J; Stepien, S; Su, WW; Sukeepaisarnjaroen, W; Tangkijvanich, P; Trépo, C; Wedemeyer, H | 1 |
| Harrison, L; Jourdain, G; Ngo-Giang-Huong, N | 1 |
| Feld, JJ; Lok, ASF; Terrault, NA | 1 |
| Gerlich, W; Glebe, D | 1 |
| Cheung, KW; Ng, EHY; Seto, MTY | 1 |
| Bae, SH; Chang, UI; Choi, JY; Jang, BH; Jang, JW; Jo, SH; Kim, CW; Kim, HJ; Kim, HY; Kim, JH; Kim, SJ; Kwon, JH; Lee, HL; Lee, HS; Lee, J; Lee, Y; Park, CH; Park, IY; Seo, KI; Sung, PS; Tekle, F; Yoon, SK | 1 |
| Asci, Z; Demir, LS; Demir, NA; Kolgelier, S; Ozcimen, S; Sumer, S; Ural, O | 1 |
| Kaplan, D | 1 |
| Henry, L; Le, A; Lee, MH; Nguyen, MH; Nguyen, N; Trinh, H; Wong, C; Yang, HI; Zhang, J | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Lee, BU; Lee, H; Lee, SB; Park, JH; Park, NH; Shin, JW | 1 |
| Caviglia, GP; Ngatchou, D; Olivero, A; Saracco, GM; Smedile, A | 1 |
| Dalekos, GN; Gatselis, N; Hadziyannis, E; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Rigopoulou, EI; Vlachogiannakos, J; Xourafas, V; Zachou, K | 1 |
| Jia, L; Li, W; Tang, H; Wu, X; Zhao, X | 1 |
| Chan, HL; Lam, KL; Lui, GC; Szeto, CC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chang, ET; Cheung, R; Chung, M; Henry, L; Hoang, J; Jeong, D; Le, AK; Lee, MH; Nguyen, MH; Trinh, S; Wang, U | 1 |
| Ahn, SH; Buti, M; Caruntu, FA; Chan, A; Chan, HLY; Chuang, WL; Crans, G; Elkhashab, M; Flisiak, R; Fung, S; Gaeta, GB; Guyer, W; Hui, AJ; Jump, B; Ma, X; Marcellin, P; Mehta, R; Papatheodoridis, G; Petersen, J; Subramanian, M; Tabak, F; Tak, WY | 1 |
| Alam, S; Khanna, R; Lal, BB; Rawat, D; Sood, V; Verma, S | 1 |
| Chen, CL; Chen, NC; Chung, TL | 1 |
| Anong, DN; Bolimo, AF; Georges, TD; Kouanou, YS; Kwenti, TE; Maurice, M; Meriki, HD; Nkuo-Akenji, T; Tony, NJ; Tufon, KA; Wung, NH | 1 |
| Goyal, A; Romero-Severson, EO | 1 |
| Flemming, JA; Terrault, NA | 1 |
| Cho, S; Choi, J; Kim, HJ; Ko, MJ; Lee, J; Lim, YS | 1 |
| Achalapong, J; Chinwong, D; Cressey, TR; Decker, L; Harrison, L; Jourdain, G; Kanjanavikai, P; Liampongsabuddhi, P; Murphy, TV; Ngo-Giang-Huong, N; Patamasingh Na Ayudhaya, O; Putiyanun, C; Salvadori, N; Siberry, GK; Siriwachirachai, T; Suriyachai, P; Tawon, Y; Tierney, C | 1 |
| Balkan, A; Gülşen, MT; Karaoğlan, İ; Namıduru, M; Şahin, A | 1 |
| Aziz, H; Aziz, M; Gill, ML; Waheed, Y | 1 |
| Cui, F; Ding, Y; Dou, X; Duan, Z; Han, G; Hou, J; Jia, J; Li, J; Li, Z; Liu, Z; Mao, Q; Wei, L; Xie, Q; Yang, X; Zhang, H; Zhuang, H | 1 |
| Bai, G; Chen, D; Ding, G; Lin, Y; Liu, K; Liu, Y; Touqui, L; Wang, W; Wu, Y; Xu, N; Zhang, L | 1 |
| Ahmed, A; Kim, D; Kim, WR; Udompap, P | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY | 1 |
| Ahn, SH; Han, KH; Jeon, MY; Kim, BK; Kim, DS; Kim, DY; Kim, SU; Lee, HW; Park, JY | 1 |
| Cabeza-Barrera, I; Cabezas-Fernández, MT; Cuenca-Gómez, JÁ; Estévez-Escobar, M; Lozano-Serrano, AB; Salas-Coronas, J; Soriano-Pérez, MJ; Vázquez-Villegas, J | 1 |
| Ahn, SH; Cho, YK; Choi, W; Han, KH; Hong, GY; Jang, JY; Jin, SY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, NH; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chang, CY; Chen, CC; Hsu, YC; Lin, JT; Mo, LR; Nguyen, MH; Tai, CM; Tanaka, Y; Tseng, CH; Wu, CY; Wu, MS; Yang, TH | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, MT; Lu, SN; Tsai, KL; Wang, JH | 1 |
| Szeto, CC; Wong, GL; Wong, VW | 1 |
| Ni, W; Wang, J; Wu, Z; Xin, H | 1 |
| Della Pepa, R; Di Perna, M; Giordano, A; Giordano, C; Lucignano, M; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, C; Trastulli, F; Zacheo, I | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Krarup, H; Mekasha, B; Pereira, AP; Stene-Johansen, K | 1 |
| McCormick, CA; McCormick, PA | 1 |
| Ahn, A; Bae, HS; Chang, M; Fong, TL; Lee, BT; Lim, C; Tien, A | 1 |
| Cai, LR; Chen, FS; Huang, Q; Li, DL; Li, YH; Wu, HC; Wu, ZX; Zeng, ZY; Zhang, SA; Zhou, XL | 1 |
| Cai, D; Dang, S; Jiang, N; Li, J; Lin, F; Pan, C; Ren, H; Shen, B; Wang, M; Wu, S; Xin, S; Yang, Y; Yu, W; Zhang, Z | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, CW; Kim, YS; Lee, HW; Lee, JI; Lee, JW; Paik, SK; Park, H; Park, JY; Yoon, KT | 1 |
| Lee, JW; Yu, JH | 1 |
| An, HY; Heo, NY; Jang, JW; Jin, YJ; Lee, JW; Suh, YJ; You, CR; Yu, JH | 1 |
| Bae, SH; Chang, UI; Cho, EY; Choi, JY; Choi, SW; Han, NI; Jang, JW; Kim, CW; Kim, HY; Kim, SG; Kim, SH; Kim, YS; Kwon, JH; Lee, BS; Lee, HL; Lee, SW; Lee, TH; Nam, SW; Song, DS; Song, MJ; Yang, JM; Yoon, SK; You, CR | 1 |
| Liang, LY; Wong, GL | 1 |
| Güner, R; Koçak Tufan, Z; Mehmet A, T; Yılmaz, GR | 1 |
| Chang, MS; Cheung, R; Hsu, H; Le, AK; Nguyen, MH; Nguyen, P; Wei, MT; Wong, C; Zhang, JQ | 1 |
| Ahn, SH; An, Y; Chae, HB; Choi, BS; Ha, YN; Jeong, N; Ju, YS; Kang, HS; Kim, DH; Kim, KH; Kim, YJ; Kwon, SY; Lee, AR; Lee, JH; Lee, YB; Park, ES; Park, S; Park, YK; Shin, GC; Sim, H; Won, J; Yoo, JJ; Yoon, JH; Yu, KS; Yu, SJ; Zoulim, F | 1 |
| Buti, M; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Gane, E; Janssen, HLA; Jump, B; Kaita, K; Kitrinos, K; Manns, M; Marcellin, P; Op den Brouw, M; Wong, DK | 1 |
| Chan, HL; Wong, GL; Wong, VW | 1 |
| Huang, R; Wang, J; Wu, C; Wu, W; Yao, R | 1 |
| Chen, CH | 1 |
| Acerbi, G; Ahn, SH; Alfieri, A; Andreone, P; Barili, V; Boni, C; Brillo, F; Brunetto, MR; Cavallone, D; Coco, B; Cursaro, C; Ferrari, C; Fisicaro, P; Fung, S; Gaggar, A; Janssen, HLA; Joshi, A; Laccabue, D; Lau, AH; Ma, X; Mangia, A; Margotti, M; Massetto, B; Pedrazzi, G; Piazzolla, V; Rodell, TC; Rossi, M; Santoro, R; Subramanian, GM; Trinh, H; Vecchi, A; Woo, J; Yoon, SK; Yoshida, EM; Zhao, Y | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Atalay, S; Köse, Ş; Tatli Kiş, T | 1 |
| Aguilera, A; Barea, L; Corral, O; Gomez-Gallego, F; Gonzalez, R; Soriano, V; Treviño, M | 1 |
| Hiraoka, A; Izumoto, H; Kitahata, S; Kondoh, K; Michitaka, K; Ninomiya, T; Tsubouchi, E; Ueki, H; Yamago, H | 1 |
| Chen, C; Chen, S; Cheng, J; Gao, Z; Hou, J; Jia, J; Li, J; Liang, X; Mao, Q; Mao, Y; Ning, Q; Niu, J; Pan, C; Ren, H; Sheng, J; Tan, D; Tang, H; Wang, H; Wu, S; Xie, Q; Xiong, C; Xu, M; Zhang, J; Zhang, W; Zhang, X; Zhao, W | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Chéret, A; Cotte, L; Delobel, P; Duvivier, C; Gantner, P; Huleux, T; Jacomet, C; Joly, V; Pugliese, P; Rey, D; Valantin, MA | 1 |
| Jia, J; Kong, Y; Yang, HI | 1 |
| Choi, J; Ko, MJ; Lim, YS | 1 |
| Hou, J; Liu, Z; Sun, J | 1 |
| Zeng, W; Zhang, H | 1 |
| Gao, ZL; Hu, ZX; Liang, XJ; Peng, L; Wu, QW; Wu, WG; Xie, C; Ye, YN; Zhang, A; Zheng, XR | 1 |
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Belle, SH; Bzowej, NH; Chung, R; Khalili, M; Li, R; Smith, CI; Terrault, N; Tran, TT; Tsai, N | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Mekasha, B | 1 |
| Abdurakhmanov, DT; Ibragimov, EK; Moiseev, SV; Nikulkina, EN; Odintsov, AV; Panevkina, SV; Rozina, TP; Tanaschuk, EL | 1 |
| Buggisch, P; Buti, M; Cathcart, AL; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Jump, B; Kaita, K; Krastev, Z; Lee, SS; Manns, M; Marcellin, P; Op den Brouw, M; Petersen, J; Sievert, W; Wong, DK | 1 |
| Hu, K; Huang, Y; Yang, J; Zhang, Z; Zhou, Y | 1 |
| Chen, X; Liu, L; Wei, M; Xu, T; Xu, Z; Zhang, C; Zhang, X | 1 |
| Fujii, T; Kawasoe, K; Nitta, K; Ohta, A | 1 |
| Dang, Z; Jiang, Y; Liu, X; Wang, X; Yan, Z; Yu, L | 1 |
| Chang, SY; Chen, GJ; Cheng, A; Chuang, YC; Huang, SH; Huang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Su, YC; Sun, HY | 1 |
| Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K | 1 |
| Lampertico, P; Wong, GL | 1 |
| Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J | 1 |
| Andersson, M; Barnes, EJ; Burn, EAO; Goedhals, D; Matthews, PC; Mokaya, J; Pinedo-Villanueva, R; Tamandjou, CR | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, EH; Kim, HY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Wyles, DL | 1 |
| Lopatin, U | 1 |
| Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P | 1 |
| Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF | 1 |
| Bertoletti, A; Borghi, M; Ceriotti, F; Ferenci, P; Giovanelli, S; Greco, L; Holzmann, H; Lampertico, P; Loglio, A; Lunghi, G; Perbellini, R; Porretti, L; Prati, D; Tham, CYL; Trombetta, E; Uceda Renteria, SC; van Bömmel, F | 1 |
| Ceriotti, F; Colombo, M; Cortinovis, I; Facchetti, F; Iavarone, M; Lampertico, P; Loglio, A; Lunghi, G; Occhipinti, V; Orenti, A; Rumi, M; Sangiovanni, A; Viganò, M | 1 |
| Choi, J; Lim, YS | 1 |
| Huang, R; Wang, J; Wu, C; Wu, W; Yan, X | 1 |
| Cloherty, G; Deerain, J; Gaggar, A; Hammond, R; Kitrinos, K; Leary, T; Locarnini, S; O'Donnell, T; Subramanian, M; Walsh, R; Wong, D; Yuen, L | 1 |
| Fan, L; Fan, Y; Jing, H; Li, C; Ma, B; Zhou, S | 1 |
| Bzowej, N; Dinh, P; Flaherty, J; Martin, P; Poordad, F; Pungpapong, S; Rossi, S; Schiano, T; Spivey, J; Subramanian, GM; Teperman, LW | 1 |
| Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Araújo de Oliveira, GL; Brandão, CM; Carmo, RA; Cherchiglia, ML; Silva, AL | 1 |
| Amarapurkar, DN; Patel, N | 1 |
| Lee, WM; Tujios, SR | 2 |
| Acalovschi, M; Arama, V; Bjork, S; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Marcellin, P; Mauss, S; Morais, E; Sieklucki, J; Simon, K; Usluer, G; Zarski, JP; Zeuzem, S | 1 |
| Costa, JB; Ferreira, AO; Marinho, RT; Velosa, J | 1 |
| Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E | 1 |
| Fontana, RJ; Kuo, YF; Salameh, H; Singal, AK | 1 |
| Al Hawajri, N; Borroto-Esoda, K; Dény, P; Kitrinos, K; Lavocat, F; Pichoud, C; Zoulim, F | 1 |
| Fung, J; Huang, FY; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Tshabalala, P; Yende-Zuma, N | 1 |
| Gracey, DM; McKenzie, P; Snelling, P; Strasser, SI | 1 |
| Horváth, G | 1 |
| Braat, AE; Claas, EC; Coenraad, MJ; Knoester, M; van Hoek, B; Vossen, AC; Wesdorp, DJ | 1 |
| Asselah, T; Marcellin, P | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Šperl, J | 1 |
| Bailly, F; Brochier, C; Cotte, L; Le Pogam, MA; Maynard, M; Miailhes, P; Okon, JB; Pradat, P; Trolliet, P; Zoulim, F | 1 |
| Buğdacı, MS; Sayan, M | 1 |
| Dixit, VK; Jain, AK; Rungta, S; Shukla, SK; Singh, TB; Srivastava, M | 1 |
| Chi, X; Hu, X; Lian, Z; Lv, J; Niu, J; Pan, Y; Sun, H; Tu, Z; Xu, D; Yan, H | 1 |
| Akkoyunlu, Y; Ceylan, B; Eren, G; Fincanci, M; Muderrisoglu, C; Tozalgan, U; Yardimci, C | 1 |
| Hwang, SG; Yim, HJ | 1 |
| Lilly, LB; Renner, EL; Selzner, N; Tanaka, T; Therapondos, G | 1 |
| Berg, T; Chan, S; Dinh, P; Flaherty, JF; Kitrinos, KM; Manns, M; Marcellin, P; McHutchison, JG; Moeller, B; Trinh, H; Zoulim, F | 1 |
| Cholongitas, E; Papatheodoridis, G; Pipili, C | 1 |
| Arama, V; Bjork, S; Bludzin, W; Habersetzer, F; Jinga, M; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Morais, E; Niederau, C; Simon, K; Ulusoy, S; Vermehren, J; Zarski, JP; Zeuzem, S | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL | 1 |
| Caruntu, FA; Corsa, A; Dinh, P; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Subramanian, GM | 1 |
| Fung, J; Lai, CL; Seto, WK; Yuen, MF | 1 |
| Buti, M | 2 |
| Lampertico, P; Mangia, G; Viganò, M | 1 |
| Colombo, M; Della Corte, C; Triolo, M | 1 |
| Esteban, R; Pérez-Cameo, C; Pons, M | 1 |
| Gao, L; Li, J; Nguyen, MH; Trinh, HN | 3 |
| Boswell, S; Crane, HM; Eron, JJ; Geng, E; Kim, HN; Kitahata, MM; Martin, J; Mathews, WC; Moore, R; Mugavero, M; Overton, ET; Rodriguez, B; Rodriguez, CV; Saag, MS; Thio, CL; Van Rompaey, S | 1 |
| Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL | 1 |
| Akyüz, F; Badur, S; Baran, B; Bozdayi, AM; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, S; Kaymakoglu, S; Keskin, O; Onel, D; Ormeci, AC; Tüzün, A; Yurdaydin, C | 1 |
| Becker, C; Hamnvik, OP; Vaidya, A | 1 |
| Price, J | 1 |
| Bielawski, KP; Dreczewski, M; Rybicka, M; Smiatacz, T; Stalke, P; Stracewska, E; Wróblewska, A | 1 |
| Strasser, SI | 1 |
| Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A | 2 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Simon, F | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Chatterjee, U; Davison, S; Glass, A; Greenup, AJ; Holdaway, S; Jackson, K; Levy, MT; Locarnini, SA; Nguyen, V; Samarasinghe, D; Strasser, SI; Tan, PK | 1 |
| Bradshaw, D; Danta, M | 1 |
| Chaikledkaew, U; Tantai, N; Tanwandee, T; Teerawattananon, Y; Werayingyong, P | 1 |
| Gupta, E; Hissar, SS; Sarin, SK; Sharma, MK; Singh, AK | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Peytavin, G; Zoulim, F | 1 |
| Lee, SS; Sadler, MD | 1 |
| Chang, HY; Kim, HJ; Lee, HW; Yang, SY | 1 |
| Dinh, P; Flaherty, JF; Fung, S; Gane, EJ; Kitrinos, KM; Liu, Y; Miller, MD; Svarovskaia, ES | 1 |
| Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S | 1 |
| Tang, CM; Yau, TO; Yu, J | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| De Vincentis, A; Dell'Unto, C; Galati, G; Gallo, P; Picardi, A; Solmone, MC; Vespasiani-Gentilucci, U; Vincenti, D | 1 |
| Cagatay, A; Ceylan, B; Erdem, L; Gokturk, K; Gunduz, A; Karaosmanoglu, H; Kocak, F; Mete, B; Ozaras, R; Ozgunes, N; Senates, E; Tabak, F | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Goulis, I; Imvrios, G; Papanikolaou, V | 1 |
| Kim, JH; Kim, KH; Park, ES; Park, YK | 1 |
| Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B | 1 |
| Ridruejo, E | 1 |
| Panda, C | 1 |
| Kekez, AJ | 1 |
| Dinçkan, A; Ersoy, F; Koçak, H; Ruhi, Ç; Süleymanlar, G; Süleymanlar, İ | 1 |
| Berg, T; van Bömmel, F | 1 |
| Gerlich, WH | 1 |
| Locarnini, S; Warner, N | 1 |
| Gürtler, LG | 1 |
| Beggel, B; Kaiser, R; Neumann-Fraune, M; Obermeier, M | 1 |
| Buti, M; de Man, RA; Dinh, P; Dusheiko, GM; Flaherty, JF; Flisiak, R; Gaggar, A; Gurel, S; Heathcote, EJ; Krastev, Z; Lin, L; Lou, L; Marcellin, P; Massetto, B; McHutchison, JG; Subramanian, GM; Zeuzem, S | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N | 1 |
| Shan, C; Wu, P; Yin, GQ | 1 |
| Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Al-Shamma, S; Barr, DA; Burke, K; Foster, GR; Gill, US; Kallis, YN; Kennedy, PT; Kooner, P; Marley, RT; McPhail, MJ; Zissimopoulos, A | 1 |
| Ao, Y; Chong, Y; Huang, M; Jie, Y; Li, X; Lin, G; Pang, Y; Shi, H; Tao, L; Wu, Y; Yang, F; Zhang, M | 1 |
| Brunetto, M; Carosi, G; Greenbloom, S; Jeffers, L; Llamoso, C; Mazur, W; Nguyen, T; Yu, S; Zoulim, F | 1 |
| Buti, M; Chan, S; Charuworn, P; Dinh, P; Flaherty, JF; Gane, E; Kitrinos, KM; Lee, SS; Marcellin, P; Subramanian, GM; Trinh, H; Tsai, NC; Washington, MK | 1 |
| Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C | 1 |
| Chi, BH; Emge, D; Mulenga, L; Mweemba, A; Vinikoor, MJ; Wandeler, G; Zanolini, A | 1 |
| Bae, HS; Chan, LS; Chang, M; Fong, TL; Huh, B; Lee, S; Lim, C; Shinada, S; Tien, C; Xu, JJ | 1 |
| Chen, CW; Chen, SJ; Cheng, J; Dong, J; Gao, ZL; Hou, JL; Ji, Y; Jia, JD; Li, J; Mao, Q; Mao, YM; Ning, Q; Niu, JQ; Pan, C; Ren, H; Sheng, JF; Tan, DM; Tang, H; Wang, H; Wu, SM; Xie, Q; Xu, M; Zhang, JM; Zhang, XX; Zhao, W | 1 |
| Eliadi, I; Polyzos, A; Samarkos, M; Theofanis, V; Vlachogiannakos, J | 1 |
| Buti, M; Dinh, P; Dusheiko, G; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; Gordon, SC; Horban, A; Jacobson, IM; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Rustgi, VK; Sperl, J; Trinh, H; Yee, LJ | 1 |
| Arslan, F; Batirel, A; Guclu, E; Karabay, O; Kocak, F; Mert, A; Ozer, S; Turanli, M | 1 |
| Deng, ZZ; Li, ZJ; Liu, SK; Ma, YT; Song, LY; Wang, CJ; Zhang, HY; Zuo, SR; Zuo, XC | 1 |
| Desmet, VJ; Grizzi, F | 1 |
| Alcantara, L; Burak, KW; Coffin, CS; Klein, P; Myers, RP; Pang, JX; Rezaeeaval, M | 1 |
| Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY | 1 |
| Chan, S; Han, SH; Krishnan, G; Li, J; Lu, L; Nguyen, MH; Pan, CQ; Trinh, H; Wong, CC; Yip, B | 1 |
| Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Kao, JH; Tseng, TC | 1 |
| Akarca, US; Elhan, AH; Gulsen, M; Gunsar, F; Idilman, R; Keskin, O; Koruk, M; Meral, CE; Yurdaydin, C | 1 |
| Enomoto, M; Hayakawa, M; Iwadate, M; Kawada, N; Murakami, Y; Tamori, A; Tanahashi, T; Umeyama, H; Yano, Y | 1 |
| Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S | 1 |
| Brocchieri, A; Castelli, F; Colombo, M; Facchetti, F; Fugazza, A; Lampertico, P; Mangia, G; Spinetti, A; Viganò, M; Zaltron, S | 1 |
| Corouge, M; Fontaine, H; Mallet, V; Pol, S; Schwarzinger, M; Sogni, P; Vallet-Pichard, A | 1 |
| Ozdogan, OC; Yegin, EG | 1 |
| Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B | 1 |
| Aguilar Schall, R; Charuworn, P; Corsa, A; Dinh, P; Ge, D; Hengen, PN; Kitrinos, KM; Reesink, HW; Zoulim, F | 1 |
| Papatheodoridis, GV; Vlachogiannakos, J | 1 |
| Invernizzi, F; Lampertico, P; Viganò, M | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| An, J; Byun, KS; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 2 |
| Cheon, GJ; Choi, K; Jang, JY; Jeong, SW; Jun, BG; Kim, BS; Kim, HS; Kim, SG; Kim, YD; Kim, YS; Lee, HM; Lee, SH | 1 |
| Andrade, JR; Barros, LM; Bertolini, DA; Carrilho, FJ; Conde, SR; de Araújo, LV; Ferreira, AC; Ferreira, AS; Galvan, J; Gomes-Gouvêa, MS; Kliemann, DA; Kunyoshi, AS; Leite, AG; Lyra, AC; Mendes-Corrêa, MC; Nastri, AC; Oikawa, MK; Piccoli, LZ; Pinho, JR; Rezende, RE; Soares, MC; Teixeira, R | 1 |
| Hwang, HS; Park, CW; Song, MJ | 1 |
| Ha, FS; Han, T; Liu, H; Liu, L; Nie, CY; Zhang, Q | 1 |
| Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W | 1 |
| Caccuri, F; Caruso, A; Castelli, F; De Francesco, MA; Gargiulo, F; Giagulli, C; Spinetti, A; Zaltron, S | 1 |
| Arends, JE; Harkisoen, S; Hoepelman, AI; van Erpecum, KJ | 1 |
| Kim, CW | 1 |
| Chang, KC; Chen, CH; Chiu, YC; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH | 1 |
| Afdhal, NH; Bornstein, JD; Buti, M; Dinh, P; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; George, J; Gurel, S; Janssen, HL; Mani Subramanian, G; Marcellin, P; Martins, EB; Yee, LJ | 1 |
| Akyuz, F; Badur, S; Baran, B; Besisik, F; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM | 1 |
| Ayaz, C; Bayan, K; Çelen, MK; Dal, MS; Dal, T; Deveci, Ö; Kandemir, I; Mert, D; Oruç, E; Özcan, N | 1 |
| Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW | 1 |
| Huang, H; Li, M; Pan, H; Wu, W; Yang, D; Zhao, N | 1 |
| Durantel, D; Zoulim, F | 1 |
| Bae, WK; Ha, SY; Jung, SK; Jwa, YJ; Kim, JW; Kim, KA; Kim, NH; Kim, YD; Lee, BH; Lee, HK; Lee, JS; Paik, WH | 1 |
| Chan, KA; Chang, CH; Chang, MH; Chen, DS; Chen, HL; Chen, SM; Hsu, JJ; Hu, JJ; Lai, MW; Lee, CL; Lee, CN; Lin, HH; Lin, HM; Mu, SC; Ni, YH; Shyu, MK; Tsai, MS; Zhao, LL | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombe, K; le Carrou, J; Maylin, S; Moh, R; Zoulim, F | 1 |
| Akın, MS; Doğan, ÜB; Öztürk, AB; Sayan, M; Yalaki, S | 1 |
| Arora, SK; Bhattacharyya, R; Chakraborti, A; Chawla, YK; Das, A; Dhiman, RK; Duseja, A; Kapil, S; Sharma, BK; Singla, B | 1 |
| Chaung, KT; Ha, NB; Kim, LH; Kin, KC; Nguyen, HA; Nguyen, MH; Trinh, HN; Vu, VD | 1 |
| Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ | 1 |
| Huits, RM; Koot, AW; Visscher, AP | 1 |
| Ha, NB; Nghiem, D; Nguyen, MH; Rosenblatt, L; Trinh, HN | 1 |
| Appiah, LT; Beloukas, A; Bhagani, S; Bonnett, L; Chadwick, D; Dusheiko, G; Geretti, AM; Phillips, RO; Sarfo, FS; Stockdale, AJ | 1 |
| Allegra, S; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G; Pensi, D; Simiele, M | 1 |
| Akıncı, H; Balık, İ; Başar, Ö; Çoban, Ş; Dökmeci, A; Güner, R; Kalkan, Ç; Örmeci, N; Özbaş, B; Özkan, H; Yalçı, A; Yüksel, İ; Yüksel, O | 1 |
| Coppolino, G; Fuiano, G; Postorino, MC; Rivoli, L; Simeoni, M; Strazzulla, A; Summaria, C; Torti, C | 1 |
| Chang, KC; Chen, CH; Chiu, KW; Chou, YP; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Buti, M; Casillas, R; Esteban, R; Homs, M; Riveiro-Barciela, M; Rodriguez-Frias, F; Salcedo, MT; Tabernero, D | 1 |
| Casazza, G; Colombo, M; de Franchis, R; Facchetti, F; Fraquelli, M; Iavarone, M; Invernizzi, F; Jovani, M; Lampertico, P; Loglio, A; Mangia, G; Primignani, M; Viganò, M | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Caroleo, B; Gallelli, L; Perticone, F; Staltari, O | 1 |
| Bae, HS; Chang, M; Cheung, E; Cho, YW; Chu, D; Cooper, SL; Fong, TL; Han, SB; Jo, KJ; LeDuc, VH; Mena, EA; Mohammed, W; Nguyen, N; Phan, QQ; Tien, A; Tong, MJ; Velasco, A; Yu, AS | 1 |
| Chan, HL; Charuworn, P; Chuang, WL; Dinh, P; Elkhashab, M; Foster, GR; Kim, YJ; Lin, L; Ma, X; Marcellin, P; Martins, EB; Tak, WY; Trinh, H | 1 |
| Georgiou, A; Hadziyannis, E; Manolakopoulos, S; Nikolopoulou, V; Papatheodoridis, G; Triantos, C; Vlachogiannakos, I; Voulgaris, T; Zisimopoulos, K | 1 |
| Boettler, T; Thimme, R | 1 |
| Cui, G; Diao, H; Xu, X | 1 |
| El Agheb, MO; Grange, JD | 1 |
| Aguilar Schall, RE; Berg, T; Buti, M; Dinh, PV; Flaherty, JF; Fung, S; Gurel, S; Jacobson, I; Kim, WR; Loomba, R; Marcellin, P; Martins, EB; Therneau, TM; Yee, LJ | 1 |
| Gross, JB; Kim, WR; Poterucha, JJ; Stadheim, LM; Wi, CI | 1 |
| Castillo, E; Coffin, CS; Lee, SS; Martin, SR; Myers, RP; Oshiomogho, JI; Osman, M; Samadi Kochaksaraei, G; Scott, AN; Simmonds, K | 1 |
| Cao, F; Chen, T; He, Y; Jin, L; Liu, J; Qi, C; Wang, J; Yan, T; Yang, Y; Zhang, S; Zhao, Y | 1 |
| Jansen, L; Kootstra, NA; Reesink, HW; Takkenberg, RB; van Dort, KA; Zaaijer, HL | 1 |
| Barreiro, P; Chagas, C; Magalhães-Costa, P; Matos, L | 1 |
| Behera, M; Dixit, VK; Ghosh, J; Goyal, SK; Gupta, N; Jain, AK; Ranjan, A; Shukla, SK; Tripathi, M | 1 |
| Warpakowski, A | 1 |
| Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P | 1 |
| Ahn, SH; Chong, Y; Kang, HS; Kim, BK; Kim, DH; Kim, KH; Lee, AR; Park, ES; Park, S; Park, YK; Rhee, JK; Shin, GC; Yang, SI | 1 |
| Boyd, A; Lacombe, K | 1 |
| Geretti, AM; Stockdale, AJ | 1 |
| Byun, SS; Jung, SW; Kim, CJ; Kim, JH; Kim, MH; Park, BR; Park, NH; Shin, JW | 1 |
| Amani, A; Niederau, C; Thiel, A | 1 |
| Ahn, SH; Buti, M; Caruntu, FA; Chan, HL; Charuworn, P; Chuang, WL; Corsa, A; Dinh, P; Elkashab, M; Flisiak, R; Foster, GR; Fung, S; Gaeta, GB; Hui, AJ; Lim, SG; Lin, L; Lou, L; Ma, X; Marcellin, P; Martins, EB; Mehta, R; Papatheodoridis, G; Petersen, J; Reesink, HW; Reiser, H; Strasser, SI; Subramanian, GM; Tabak, F; Tak, WY; Trinh, H | 1 |
| Yin, GQ; Zhong, B | 1 |
| Deshpande, S; Horne, K; Kiss, C; Ko, T; Lau, JS; Ratnam, D; Roberts, E; Williams, J; Woolley, I | 1 |
| Kosinska, AD; Liu, J; Lu, M; Roggendorf, M | 1 |
| Abe, H; Aikata, H; Akita, T; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kan, H; Kawaoka, T; Masaki, K; Miki, D; Murakami, E; Nakahara, T; Ochi, H; Ono, A; Tanaka, J; Tsuge, M; Uchida, T | 1 |
| Park, JG; Park, SY | 1 |
| Hutton, DW; So, SK; Toy, M | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, D Y; Kim, SU; Ku, HJ; Lee, S; Park, JY; Song, K | 1 |
| Boeker, K; Eisenbach, C; Felten, G; Hartmann, H; Heyne, R; Hueppe, D; John, C; Krause, W; Leuschner, M; Loehr, HF; Mauss, S; Petersen, J; Ruppert, S; Schiffelholz, W; Schlaak, J; Trautwein, C; Trein, A; Warger, T; Wiese, M | 1 |
| Halota, W; Kozielewicz, D; Wietlicka-Piszcz, M | 1 |
| McMahon, BJ | 1 |
| Lu, X; Ning, Q; Wang, HL; Yang, X | 1 |
| Chaung, KT; Ha, NB; Nguyen, MH; Nguyen, NH; O'Brien, C; Trinh, HN | 1 |
| Kittitrakul, C; Leowattana, W; Nontprasert, A; Phumratanaprapin, W; Poovorawan, K; Sriboonvorakul, N; Tangkijvanich, P; Thu, AM; Wilairatana, P | 1 |
| Menne, S; Paulsen, D; Ruebsamen-Schaeff, H; Tennant, BC; Weber, O | 1 |
| Arslan, F; Batırel, A; Ceylan, B; Fersan, E; Fincancı, M; Mert, A; Paşaoğlu, E; Yardımcı, C; Yılmaz, M | 1 |
| Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskin, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papatheodoridis, G; Savvidou, S; Sypsa, V; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, HM; Wang, JH; Yen, YH | 1 |
| Béguelin, C; Moradpour, D; Rauch, A; Sahli, R; Suter, F; Vazquez, M; Wandeler, G | 1 |
| Ahn, SH; Bae, SH; Han, KH; Jung, KS; Kim, CW; Kim, HY; Park, JY; Yoon, SK | 1 |
| Anderson, PL; Kiser, JJ; Lan, A; Naggie, S; Patel, K; Tillman, H; Wong, TC | 1 |
| Bourlière, M; Cadranel, JF; Causse, X; Consoli, SM; Dumortier, J; Hézode, C; Larrey, D; Libert, O; Marcellin, P; Ouzan, D; Pageaux, GP; Pauwels, A; Pétour, P; Riachi, G; Roche, B; Stern, C; Tilliet, V; Truchi, R; Zarski, JP; Zoulim, F | 1 |
| Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE | 1 |
| Chauhan, R; Kumar, M; Rooge, S; Sarin, SK; Singh, AK; Varshney, A | 1 |
| Cainelli, F; Vento, S | 1 |
| Audsley, J; Avihingsanon, A; Bayliss, J; Bent, SJ; Bowden, S; Fairley, CK; Lewin, SR; Littlejohn, M; Locarnini, S; Luciani, F; Matthews, G; Sasadeusz, J; Yuen, L | 1 |
| Cao, Y; Dai, CY; Hou, W; Jiang, B; Li, XM; Lu, W; Su, R; Xu, J | 1 |
| Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R | 1 |
| Chong, Y; Huang, M; Jie, Y; Li, X; Lin, G; Shi, H; Wu, Y | 2 |
| Bae, MA; Chung, HS; Jung, SW; Lee, YI; Park, CH; Park, NH; Park, YT; Shin, JW | 1 |
| Aykın, N; Çevik, F; Demirtürk, N; Doğan, N; Koca, B; Köken, T | 1 |
| Almeida, PR; Dal-Pupo, BB; Grossmann, TK; Mattos, AA; Mirenda, H; Pereira, CV; Tovo, CV | 1 |
| Beraud, G; Chagneau-Derrode, C; Garcia, M; Godet, C; Le Moal, G; Roblot, F | 1 |
| Berg, T; Chan, HL; Janssen, HL; Lampertico, P; Schindler, R; Strasser, SI | 1 |
| Bendahmane, S; Białkowska-Warzecha, J; Diculescu, MM; Goldis, AE; Heyne, R; Janssen, HL; Klauck, I; Mach, T; Marcellin, P; Petersen, J; Simon, K; Wasiak, W; Zoulim, F | 1 |
| Atay, K; Canbakan, B; Durcan, E; Gültepe, İ; Hatemi, İ; Köroğlu, E; Özdemir, S; Sonsuz, A; Tuncer, M; Yurttaş, B | 1 |
| Boeijen, LL; Boonstra, A; de Knegt, RJ; Janssen, HL; Reijnders, JG; Tjwa, ET; van Campenhout, MJ; van Oord, GW; Woltman, AM; Zoutendijk, R | 1 |
| Defresne, F; Sokal, E | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S | 1 |
| Ahn, SH; Choe, WH; Kim, JH; Kim, KH; Ko, SY; Kwon, SY | 1 |
| Dai, E; Duan, Z; Han, G; Jiang, H; Pan, CQ; Wang, Y; Zhang, H; Zhang, S; Zhao, W; Zhu, B; Zou, H | 1 |
| Arenas Ruiz Tapiador, J; Bonet Vidal, ML; Buti, M; Calleja, JL; Castro, Á; Crespo, J; Del Pino-Montes, J; Delgado Blanco, M; Diago, M; Fernández-Rodríguez, C; Fraga, E; García-Samaniego, J; González Diéguez, L; Morillas, R; Núñez, O; Pascasio, JM; Praga, M; Prieto, M; Rodríguez-Nóvoa, S; Romero-Gómez, M; Solá, R | 1 |
| Chemin, I; Diop, M; Ghosh, S; Guillot, C; Jeng, A; Kane, CT; Lemoine, M; Mboup, S; Mendy, M; Ndow, G; Njie, R; Sow, A; Thursz, M; Toure, S; Zoulim, F | 1 |
| Yim, HJ | 1 |
| Cho, EJ; Cho, H; Cho, Y; Kim, YJ; Lee, JH; Lee, K; Mustika, S; Oh, KH; Yoon, JH; Yu, SJ | 1 |
| Chen, YC; Chien, RN; Hu, TH; Jeng, WJ; Liaw, YF; Lin, CL; Sheen, IS | 1 |
| Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Giakoustidis, D; Giouleme, O; Goulis, I; Imvrios, G; Papanikolaou, V; Vasiliadis, T | 1 |
| Chang, CY; Chen, TB; Hsu, YC; Lin, JT; Mo, LR; Tseng, CM | 1 |
| Chen, B; Ju, JC; Qi, JH; Xu, L; Zhang, NN | 1 |
| den Eynde, EV; Riveiro-Barciela, M | 1 |
| Brahmania, M; Brouwer, WP; Feld, J; Hansen, T; Janssen, HL; Kowgier, M; Mazzulli, T; Wong, D | 1 |
| Bayliss, J; Buti, M; Colledge, D; Edwards, R; Gaggar, A; Gane, E; Hammond, R; Jackson, K; Janssen, HLA; Kitrinos, KM; Littlejohn, M; Locarnini, S; Marcellin, P; Revill, PA; Rosenberg, G; Sozzi, V; Subramanian, GM; Thompson, A; Wong, D; Yuen, L | 1 |
| Berg, T; Caruntu, FA; Elkhashab, M; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Jablkowski, MS; Kim, K; Kitrinos, KM; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Sporea, I; Subramanian, GM; Yee, LJ; Yurdaydin, C | 1 |
| Collado Borrell, R; Gutiérrez García, ML; López Centeno, B; Pérez Encinas, M; Sanmartin Fenollera, P | 1 |
| Chitturi, S; Farrell, GC; Kaye, G; Ooi, M; Shadbolt, B; Teoh, NC; Truong, J | 1 |
| Chen, J; Li, M; Xi, H; Xu, X; Zhang, R; Zhang, X; Zhang, Y | 1 |
| Agarwal, K; Ahn, SH; Buti, M; Caruntu, FA; Chan, HL; Charuworn, P; Chuang, WL; Elkhashab, M; Flisiak, R; Foster, GR; Fung, S; Gaeta, GB; Hui, AJ; Idilman, R; Lee, CM; Lim, SG; Lin, L; Ma, X; Marcellin, P; Martins, EB; Mehta, R; Morano, L; Papatheodoridis, G; Petersen, J; Samuel, D; Strasser, SI; Tabak, F; Tak, WY; Wu, G; Yee, LJ | 1 |
| Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH | 1 |
| Ahn, SH; Baatarkhuu, O; Han, K; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Ku, HJ; Lee, S; Park, JY | 1 |
| Altınel, Ç; Demirkoparan, Ü; Karasu, Z; Turan, İ | 1 |
| He, J; Li, K; Li, W; Ning, HB; Shang, J; Zeng, YL | 1 |
| Asano, M; Dohi, T; Enomoto, N; Gatanaga, H; Honda, M; Inoue, T; Kaneko, S; Kawamura, YI; Matsumoto, A; Mizokami, M; Murata, K; Nishida, N; Oka, S; Sakamoto, M; Shirasaki, T; Shuno, Y; Sugiyama, M; Tanaka, E; Yano, H | 1 |
| Buchanan, R; Khakoo, SI; Naftel, J | 1 |
| Chan, CC; Pagnoux, C; Wei, DW | 1 |
| Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A | 1 |
| Chen, Y; Ding, H; Han, Y; Liao, H; Liu, Y; Zeng, A | 1 |
| Anania, FA; Pearlman, BL; Pillai, AA | 1 |
| Chinnaratha, MA; Fraser, RJ; Kaambwa, B; Wigg, AJ; Woodman, RJ | 1 |
| Adinolfi, LE; Andreana, L; Boemio, A; Guerrera, B; Marrone, A; Pasquale, G; Rainone, I; Rinaldi, L; Ruggiero, G; Zampino, R | 1 |
| Jung, YK; Kang, K; Kim, D; Kim, DH; Lee, J; Suh, SJ; Yim, HJ | 1 |
| Chen, GF; Lau, G; Wang, C | 1 |
| Acero, D; Aguirre, A; Buti, M; Calleja, JL; Comas, C; Crespo, J; de Cuenca, B; Esteban, R; Fernandez-Bermejo, M; García-Samaniego, J; Gutierrez, ML; Lens, S; Manzano, ML; Moreno, D; Moreno-Palomares, JJ; Pascasio, JM; Piqueras, B; Riveiro-Barciela, M; Rivero, M; Rodríguez, FG; Sánchez-Pobre, P; Suárez, E; Tabernero, D | 1 |
| Song, BC | 1 |
| Ahn, HJ; Bae, SH; Choi, JY; Jang, JW; Song, MJ; Yoon, SK | 1 |
| Dixit, VK; Jain, AK; Nath, G; Singh, N; Srivastava, M | 1 |
| Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A | 1 |
| Lim, YS | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Wu, IT | 1 |
| Cho, EJ; Cho, Y; Chung, GE; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, M; Yoo, JJ; Yoon, JH; Yu, SJ; Zoulim, F | 1 |
| Basile, M; Cicchetti, A; Coretti, S; Drago, C; Ruggeri, M | 1 |
| Atkinson, A; Battegay, M; Béguelin, C; Bernasconi, E; Calmy, A; Cavassini, M; Friolet, N; Günthard, HF; Lüthi, A; Moradpour, D; Rauch, A; Sahli, R; Schmid, P; Suter-Riniker, F; Wandeler, G | 1 |
| Afdhal, N; Aguilar Schall, R; Akarca, US; Buti, M; Flaherty, JF; Flisiak, R; Jacobson, IM; Marcellin, P; McHutchison, JG; Myers, RP; Patel, K; Subramanian, GM; Tchernev, KG; Thompson, A; Washington, MK; Younossi, Z | 1 |
| Chen, J; Diao, H; Fan, J; Fu, X; Guo, R; Li, L; Li, Y; Yan, D; Yang, J; Yao, X | 1 |
| Jang, MK; Kim, DJ; Kim, HS; Kim, SE; Kwak, KM; Lee, MS; Park, CK; Park, JW; Park, SH; Suk, KT | 1 |
| Banerjee, P; Banerjee, S; Chakrabarti, S; Chakraborty, A; Chowdhury, A; Das, K; Datta, S; Ghosh, S; Khatun, M; Mondal, RK; Mukherjee, S; Pandit, P | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA | 1 |
| Butler, SD; Cote, PJ; George, AL; Gerin, JL; Menne, S; Tennant, BC; Tochkov, IA; Xiong, S; Zhu, Y | 1 |
| Deterding, K; Manns, MP; Wedemeyer, H | 1 |
| Dieterich, DT; Han, SH; Jacobson, IM; Keeffe, EB; Martin, P; Schiff, ER; Tobias, H | 1 |
| Canbay, A; Gerken, G; Gerlich, WH; Jochum, C; Katsounas, A; Schlaak, J | 1 |
| Anderson, J; Buggisch, P; Buti, M; de Man, RA; Flisiak, R; Gane, E; Germanidis, G; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Quinn, J; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Washington, MK; Weilert, F | 1 |
| Lai, CL; Yuen, MF | 1 |
| Amini-Bavil-Olyaee, S; Lutz, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Sarmento E Castro, R; Sheldon, J; Soriano, V | 1 |
| González-Diéguez, ML; Rodríguez, M | 1 |
| Buster, EH; Janssen, HL; Schalm, SW | 1 |
| Colombo, M; Lampertico, P | 1 |
| Lampertico, P | 1 |
| Zarski, JP | 1 |
| Moreno, V; Valencia, ME | 1 |
| Ham, MY; Holt, C; Saab, S; Stone, MA; Tong, M | 1 |
| Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y | 1 |
| Buffet, C | 1 |
| Brosa, M; Buti, M; Casado, MA; Esteban, R; Rueda, M | 1 |
| Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G | 1 |
| Lok, AS; McMahon, BJ | 1 |
| Cheng, J; Liang, ZL; Liu, Y; Ren, XQ; Wang, CM; Xu, DP; Xu, ZH; Zhong, YW; Zoulim, F | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Jenh, AM; Pham, PA; Thio, CL | 1 |
| Perry, CM; Simpson, D | 1 |
| Lin, Q; Zhang, DZ | 1 |
| Adusumilli, S | 1 |
| Funk, A; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Zöllner, B | 1 |
| Lau, GK | 1 |
| Marcellin, P; Piratvisuth, T; Sung, J | 1 |
| Marcellin, P; Perrillo, RP | 1 |
| Gómez Espín, R; Muñoz Bertrán, E; Ortega González, I; Pérez Ceballos, E | 1 |
| Chan, HL; Han, KH; Hou, JL; Kao, JH; Lui, YY; Mihm, U; Mohamed, R; Piratvisuth, T; Teo, EK; Tsoi, KK; Wong, GL; Wong, VW | 1 |
| Benhamou, Y; Izzedine, H; Peytavin, G; Schneider, L; Thibault, V; Valantin, MA | 1 |
| Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J | 1 |
| Chien, RN | 1 |
| Berg, T; Borroto-Esoda, K; Chan, S; Frederick, D; Lavocat, F; Marcellin, P; Moller, B; Oldach, D; Rousseau, F; Snow-Lampart, A; Sorbel, J; Suarez, E; Trinh, H; Zoulim, F | 1 |
| Einarson, TR; Heathcote, EJ; Kowgier, M; Krahn, M; Nishikawa, Y; Pham, B; Sherman, M; Tomlinson, G; Ungar, WJ; Wong, DK; Woo, G | 1 |
| Chen, EQ; Tang, H | 1 |
| Cacoub, P; Carrat, F; Goderel, I; Lacombe, K; Loustau-Ratti, V; Miailhes, P; Morlat, P; Piroth, L; Pol, S; Rami, A; Rey, D; Rosenthal, E; Sene, D | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Hoepelman, AI; Janssen, HL; Mulder, JW; Pas, SD; Prins, JM; Reijnders, JG; Richter, C; Schutten, M; van der Ende, ME; Zaaijer, HL | 1 |
| Bentley, A; Dakin, H; Dusheiko, G | 1 |
| Dakin, H; Fidler, C; Harper, C | 1 |
| Belvisi, V; Cenfra, N; Cimino, G; Del Borgo, C; Lichtner, M; Marocco, R; Mastroianni, CM; Mecarocci, S; Rago, A | 1 |
| Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K | 1 |
| Boroń-Kaczmarska, A; Cianciara, J; Flisiak, R; Gładysz, A; Halota, W; Juszczyk, J; Kryczka, W; Malkowski, P; Pawlowska, M; Simon, K | 1 |
| Einecke, D | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Tacke, F; Trautwein, C | 1 |
| Chotiyaputta, W; Ditah, FA; Goodwin, D; Lok, AS; Peterson, C | 1 |
| Jenh, AM; Pham, PA | 1 |
| Anderson, J; Borroto-Esoda, K; Buggisch, P; Buti, M; De Man, RA; Flisiak, R; Gane, E; Germanidis, G; Gurel, S; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Weilert, F | 1 |
| Bonacini, M | 1 |
| Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI | 1 |
| Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Bourlière, M; Kahloun, A; Zoulim, F | 1 |
| Benhamou, Y; Pais, R | 1 |
| Marcellin, P | 1 |
| Borchert, K; Freund, M; Hilgendorf, I; Junghanss, C; Loebermann, M; Schmitt, M | 1 |
| Janssen, HL; Rijckborst, V; Sonneveld, MJ | 1 |
| Janssen, HL; Sonneveld, MJ | 1 |
| Leung, N | 1 |
| Zoulim, F | 1 |
| Mutimer, D | 1 |
| Bettocchi, D; Consales, G; Durval, A; Luzzio, MG; Zamidei, L | 1 |
| Akarca, US; Berg, T; Buti, M; Chang, TT; Frederick, D; Horban, A; Kitrinos, K; Kwan, P; Lee, CM; Liaw, YF; Mondou, E; Papatheodoridis, GV; Peschell, K; Prieto, M; Rousseau, F; Schiff, ER; Sheen, IS; Suet-Hing Wong, F; Wang, C | 1 |
| Alberti, A; Brunetto, M; Bruno, R; Cariti, G; Carosi, G; Colombo, M; Craxì, A; Di Marco, V; Ferrari, C; Filice, G; Gaeta, GB; Lampertico, P; Levrero, M; Marzano, A; Mazzotta, F; Pastore, G; Piccinino, F; Pollicino, T; Prati, D; Puoti, M; Raimondo, G; Rizzetto, M; Sagnelli, E; Santantonio, T; Smedile, A; Toti, M | 1 |
| Garg, H; Garg, V; Kumar, A; Kumar, M; Sarin, SK; Sharma, BC | 1 |
| Hissar, SS; Khanam, A; Kotillil, S; Mishra, SK; Sarin, SK; Shrivastava, S; Sukriti, S; TrehanPati, N | 1 |
| Hosaka, T; Kumada, H; Suzuki, F | 1 |
| Alric, L; Basse, G; Daudé, M; Esposito, L; Guitard, J; Izopet, J; Kamar, N; Lavayssière, L; Rostaing, L; Sauné, K | 1 |
| Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ | 1 |
| Liu, T; Wang, Y; Zhang, C | 1 |
| Borroto-Esoda, K; Chappell, B; Curtis, M; Heathcote, J; Kitrinos, K; Marcellin, P; Miller, MD; Myrick, F; Schawalder, J; Snow-Lampart, A; Sorbel, J; Svarovskaia, ES; Zhu, Y | 1 |
| Chen, LZ; Dai, XH; Fan, XG; Tang, LH; Wang, W; Zhao, SS; Zhou, RR | 1 |
| Desire, N; Katlama, C; Stitou, H; Thibault, V; Tubiana, R; Valantin, MA | 1 |
| Tornai, I | 1 |
| Andreoni, M; Bertoli, A; Ceccarelli, L; Perno, CF; Salpini, R; Sarrecchia, C; Sordillo, P; Svicher, V; Volpi, A | 1 |
| Benetti, S; Cassino, L; Fay, F; Quarleri, J; Tanno, H | 1 |
| Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G | 1 |
| Boucher, CA; Hansen, BE; Janssen, HL; van Vuuren, AJ; Zoutendijk, R | 1 |
| Chan, HL; Chan, HY; Locarnini, SA; Tse, CH; Wong, GL; Wong, VW; Yuen, LK | 1 |
| Bailly, F; Buti, M; Cruiziat, C; Deterding, K; Dumortier, J; Esteban, R; Janssen, HL; Mallet, V; Pradat, P; Si-Ahmed, SN; Wedemeyer, H; Zoulim, F; Zoutendijk, R | 1 |
| Giles, M; Sasadeusz, J; Visvanathan, K | 1 |
| Borroto-Esoda, K; Curtis, M; Zhu, Y | 1 |
| Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW | 1 |
| da Silva, AC; Gianini, RJ; Gomes-Gouvea, MS; Guastini, CF; Leite, AG; Martins, LG; Mendes-Correa, MC; Pinho, JR; Silva, MH; Uip, DE | 1 |
| Berg, T; Brown, A; Buggisch, P; Buti, M; Janssen, HL; Lampertico, P; Lutgehetmann, M; Petersen, J; Ratziu, V; Sarrazin, C; Schollmeyer, J; Sterneck, M; Wedemeyer, H; Zoulim, F | 1 |
| Lee, SS; Sherman, M | 1 |
| Bentley, A; Dakin, H; Fidler, C; Fung, S; Sherman, M | 1 |
| Suzuki, F | 2 |
| Campanale, F; D'Addiego, G; Fazio, V; Giammario, A; Scotto, G | 1 |
| Brunetto, MR; Janssen, HL; Sonneveld, MJ | 1 |
| Arasli, M; Buyukuysal, C; Delikanli, B; Harmandar, F; Ustundag, Y | 1 |
| Cox, N; Tillmann, H | 1 |
| Fontana, RJ; Singal, AK | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Bunchorntavakul, C; Chen, W; Hu, KQ; Pan, CQ; Reddy, KR; Yu, AS | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Lascoux-Combe, C; Lassel, L; Lavocat, F; Maylin, S; Miailhes, P; Zoulim, F | 1 |
| Ridruejo, E; Silva, MO | 1 |
| Lampertico, P; Liaw, YF | 1 |
| Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X | 1 |
| Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE | 1 |
| Fernandes, CA; Gomes, Sde A; Mello, FC | 1 |
| Corsa, AC; Dinh, P; Luminos, LM; McHutchison, J; Mizerski, J; Murray, KF; Pang, PS; Pawlowska, M; Rossi, S; Szenborn, L; Wysocki, J | 1 |
| Lampertico, P; Pol, S | 1 |
| Hadziyannis, SJ | 1 |
| Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V | 1 |
| Rosenthal, P | 1 |
| Almasio, PL; Bertino, G; Brandolino, N; Bruno, S; Caroleo, B; Cosco, L; Di Marco, V; Foti, G; Frugiuele, P; Galdieri, A; Madonia, S; Montalto, G; Portelli, V; Russello, M; Sapienza, M; Scifo, G; Siciliano, R; Spadaro, A; Stroffolini, T; Surace, L | 1 |
| Ducos, J; Kania, D; Kuster, N; Lozano, C; Mondain, AM; Nagot, N; Pageaux, GP; Poinso, A; Reynes, J; Tuaillon, E; Van de Perre, P | 1 |
| Alfieri, A; Boni, C; Brancaccio, G; Colombo, M; Ferrari, C; Gaeta, GB; Giuberti, T; Laccabue, D; Lampertico, P; Missale, G; Pesci, M; Schivazappa, S; Viganò, M | 1 |
| Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Giacobbe, DR; Mikulska, M; Taramasso, L; Viscoli, C | 1 |
| Bozdayi, AM; Cevik, E; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, SC; Seven, G; Yakut, M; Yurdaydin, C | 1 |
| Buti, M; Homs, M | 1 |
| Ahmed, A; Chaung, K; Cheung, R; Nguyen, HA; Nguyen, MH; Trinh, HN; Wong, CR; Yip, B | 1 |
| Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O | 1 |
| Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM | 1 |
| Hu, KQ; Pan, CQ; Tsai, N | 1 |
| Bahrami, S; Chevaliez, S; Grare, M; Hézode, C; Pawlotsky, JM | 1 |
| Afdhal, N; Aguilar Schall, R; Bornstein, JD; Buti, M; Flaherty, JF; Gane, E; Germanidis, G; Heathcote, EJ; Jacobson, IM; Kitrinos, KM; Marcellin, P; McHutchison, JG; Sievert, W; Subramanian, GM; Washington, MK | 1 |
| Hoofnagle, JH; Tana, MM | 1 |
| Buti, M; Petersen, J | 1 |
| Coffin, CS; Fung, SK; Ma, MM | 1 |
| Colle, I; Gamil, M; Horsmans, Y; Hulstaert, F; Nevens, F; Schwierz, C; Thiry, N; Van de Sande, S | 1 |
| Berg, T; Borroto-Esoda, K; Curtis, M; Kitrinos, KM; Lavocat, F; Miller, MD; Svarovskaia, ES; Zhu, Y; Zoulim, F | 1 |
| Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL | 1 |
| Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Cui, YJ; Song, ZL; Teng, DH; Zheng, H; Zheng, WP | 1 |
| Buti, M; Casado, MA; Lozano, V; Oyagüez, I | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM | 1 |
| Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S | 1 |
| Díaz, B; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P | 1 |
| Atkins, M; Barr, A; Bower, M; Fisher, M; Gazzard, B; Matthews, G; Nelson, M; Pillay, D; Portsmouth, S; Stebbing, J | 1 |
| Bruno, R; Ciappina, V; Filice, G; Puoti, M; Sacchi, P; Zocchetti, C | 1 |
| Crippin, J; Drechsler, H; Lisker-Melman, M; Ristig, M; Tebas, P | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| Benhamou, Y; Poynard, T | 1 |
| Chung, RT; Dienstag, JL; Kuo, A | 1 |
| Cheng, AK; Cooper, DA; DeJesus, E; Dore, GJ; Lu, B; Miller, MD; Pozniak, AL; Zhong, L | 1 |
| Thio, CL | 1 |
| Ala, A; Dieterich, DT | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A | 1 |
| Lok, AS | 1 |
| Berger, A; Brodt, HR; Lennemann, TS; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; Stürmer, M | 1 |
| Harangozo, CS; Korman, TM; Moyle, M; Veitch, AJ; Woolley, IJ | 1 |
| Benhamou, Y; Bonyhay, L | 1 |
| Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG | 1 |
| Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Del Poggio, P; Jamoletti, C; Zaccanelli, M | 1 |
| Boelle, PY; Girard, PM; Gozlan, J; Lacombe, K; Serfaty, L; Valleron, AJ; Zoulim, F | 1 |
| Butler, SD; Cote, PJ; Delaney, WE; George, AL; Gerin, JL; Korba, BE; Menne, S; Tennant, BC; Tochkov, IA; Xiong, S | 1 |
| de Man, RA; Hansen, BE; Janssen, HL; Niesters, HG; Schalm, SW; van de Ende, M; van der Eijk, AA | 1 |
| Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Gerlich, WH; Hartmann, H; Schildgen, O | 1 |
| Roche, B; Samuel, D | 1 |
| Sherman, M | 1 |
| Butt, AA | 1 |
| Funk, A; Gerlich, WH; Hartmann, H; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Wend, UC; Will, H; Willems, WR | 1 |
| Lee, WA; Martin, JC | 1 |
| Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E | 1 |
| Barreiro, P; Camino, N; Díaz-Pollán, B; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Ramos, B; Soriano, V | 1 |
| Alston-Smith, B; Andersen, J; Brosgart, CL; Jacobson, JM; Johnson, VA; Liu, T; Lynch, P; Peters, MG; Pollard, RB; Polsky, B; Rooney, JF; Sherman, KE; Swindells, S | 1 |
| Benhamou, Y | 1 |
| Durantel, S; Girard, PM; Gozlan, J; Lacombe, K; Ollivet, A; Tran, N; Zoulim, F | 1 |
| Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ | 1 |
| Berger, A; Faust, D; Stuermer, M; Teuber, G; Trojan, J | 1 |
| Chaix, ML; Correas, JM; Dhalluin-Venier, V; Mallet, VO; Pol, S; Verkarre, V; Viard, JP | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Daniels, E; Gaglio, PJ; Sterling, R; Tedaldi, E | 1 |
| Bozdayi, AM; Karaaslan, H; Karatayli, E; Karayalçin, S; Kayhan, H; Sahin, F; Türkyilmaz, AR; Yurdaydin, C | 1 |
| Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG | 1 |
| Janssen, HL; Reijnders, JG | 1 |
| Degertekin, B; Husain, M; Lok, AS; Oberhelman, K; Tan, J; Wong, SN | 1 |
| Byun, KS; Choe, WH; Kim, BK; Kim, GH; Ko, SY; Kwon, SY; Lee, CH; Yeon, JE | 1 |
| Goto, T; Kato, N; Omata, M | 1 |
| Mauss, S | 1 |
| Ayoub, WS; Keeffe, EB | 1 |
164 review(s) available for tenofovir and Chronic Hepatitis B
| Article | Year |
|---|---|
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir; Treatment Outcome | 2022 |
Low-level viremia in nucleoside analog-treated chronic hepatitis B patients.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Tenofovir; Treatment Outcome; Viremia | 2021 |
Clinical management of chronic hepatitis B: A concise overview.
Topics: Aged; Antiviral Agents; Asymptomatic Diseases; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Esophageal and Gastric Varices; Hepatic Encephalopathy; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Liver Neoplasms; Male; Seroconversion; Tenofovir; Withholding Treatment | 2022 |
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Thailand; Treatment Outcome | 2022 |
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Safety of current antiviral drugs for chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Randomized Controlled Trials as Topic; Symptom Flare Up; Tenofovir; Treatment Outcome | 2022 |
Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2022 |
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Pre-Exposure Prophylaxis; Risk Assessment; Tenofovir | 2022 |
Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Bone Density; Bone Diseases, Metabolic; Hepatitis B, Chronic; Humans; Kidney; Osteoporosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Two-drug regimens for HIV treatment.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Tenofovir | 2022 |
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Tertiary Prevention; Treatment Outcome | 2023 |
The Different Prognoses of Hepatocellular Carcinoma with Previous Tenofovir versus Entecavir Treatment for Chronic Hepatitis B Virus: Analysis Based on 15 Propensity Score-Matched Studies.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Prognosis; Propensity Score; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B.
Topics: Adenine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Tenofovir | 2023 |
Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2023 |
Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interleukin-10; Leukocytes, Mononuclear; Liver Neoplasms; Nucleosides; Proto-Oncogene Proteins c-akt; Tenofovir; TOR Serine-Threonine Kinases; Treatment Outcome | 2023 |
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; Humans; Tenofovir; Triglycerides | 2023 |
HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2023 |
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2023 |
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Network Meta-Analysis; Tenofovir; Treatment Outcome | 2023 |
Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis.
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; End Stage Liver Disease; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Retrospective Studies; Severity of Illness Index; Tenofovir; Treatment Outcome | 2023 |
[Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile].
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2023 |
Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Tenofovir; Treatment Outcome | 2019 |
Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2019 |
[Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Proportional Hazards Models; Tenofovir; Treatment Outcome | 2019 |
Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.
Topics: Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Randomized Controlled Trials as Topic; Seroconversion; Tenofovir; Treatment Outcome | 2020 |
Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis.
Topics: Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk; Tenofovir | 2021 |
Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.
Topics: Adult; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Telbivudine; Tenofovir; Treatment Outcome | 2020 |
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Comorbidity; Female; Forecasting; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk; Tenofovir | 2020 |
Hepatocellular carcinoma and multiple myeloma with elevated globulin: a case report and literature review.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Hepatocellular; Diagnosis, Differential; DNA, Viral; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiofrequency Ablation; Tenofovir; Ultrasonography | 2020 |
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Topics: Alanine; Antiviral Agents; Asia; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Topics: Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Tenofovir | 2021 |
The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Duration of Therapy; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Public Health Practice; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2020 |
Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Network Meta-Analysis; Tenofovir | 2021 |
Efficacy and Safety of Tenofovir in the Prevention of Perinatal Transmission of Hepatitis B, a Meta-Analysis.
Topics: Antiviral Agents; Confidence Intervals; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Observational Studies as Topic; Pregnancy; Pregnancy Complications, Infectious; Publication Bias; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Observational Studies as Topic; Risk Assessment; Tenofovir; Treatment Outcome | 2020 |
No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Risk Factors; Tenofovir | 2021 |
Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
What would be the impact of COVID-19 on liver function of a patient with chronic hepatitis B? About a case and literature review.
Topics: Adult; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Hepatitis B, Chronic; Hospitals, University; Humans; Hydroxychloroquine; Liver Function Tests; Male; Morocco; Tenofovir | 2021 |
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation | 2017 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Retrospective Studies; Survival Analysis; Telbivudine; Tenofovir; Thymidine | 2017 |
Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission.
Topics: Antiviral Agents; Endemic Diseases; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization; Immunoglobulins; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Telbivudine; Tenofovir; Thymidine; Viral Load | 2017 |
Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus.
Topics: Combined Modality Therapy; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Time Factors | 2017 |
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Randomized Controlled Trials as Topic; Tenofovir | 2017 |
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Viral Load | 2017 |
Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Male; Osteoporosis; Patient Safety; Pregnancy; Renal Insufficiency; Risk Factors; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Molecular Conformation; Tenofovir | 2017 |
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chronic; Humans; Prodrugs; Renal Insufficiency; Tenofovir | 2018 |
Why not to stop antiviral treatment in patients with chronic hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Recurrence; Tenofovir; Treatment Outcome | 2018 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries.
Topics: Alanine Transaminase; Antiviral Agents; Creatine Kinase; Creatinine; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load | 2018 |
Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus.
Topics: Algorithms; Antiviral Agents; Breast Feeding; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Immunologic Factors; Infant, Newborn; Infectious Disease Transmission, Vertical; Mass Screening; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Vaccination; Viral Load | 2019 |
Unmet need in chronic hepatitis B management.
Topics: Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Prognosis; Renal Insufficiency, Chronic; Tenofovir | 2019 |
The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
Topics: Adult; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir | 2019 |
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Nucleotides; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2020 |
Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Topics: Adenine; Antiviral Agents; Bayes Theorem; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Network Meta-Analysis; Organophosphonates; Prospective Studies; Telbivudine; Tenofovir | 2019 |
Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease.
Topics: Anti-Retroviral Agents; Coinfection; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Prevalence; Prognosis; Risk Assessment; Survival Analysis; Tenofovir; Treatment Outcome | 2019 |
Drugs in the Pipeline for HBV.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Forecasting; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Tenofovir; Treatment Outcome; Virus Replication | 2019 |
Update in the management of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon Type I; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2013 |
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
[Interdisciplinary aspects of and new drugs for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Gastroenterology; Guanine; Hematology; Hepatitis B, Chronic; Humans; Hungary; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Interdisciplinary Communication; Interferons; Lamivudine; Medical Oncology; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rheumatology; Tenofovir | 2013 |
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome; Virus Replication | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
[Reactivation of chronic hepatitis B].
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Biomarkers; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Inflammation; Lamivudine; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2013 |
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Nucleosides; Organophosphonates; Tenofovir; Virus Replication | 2013 |
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine | 2014 |
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
Topics: Acidosis, Lactic; Adenine; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Muscular Diseases; Nervous System Diseases; Nucleosides; Nucleotides; Organophosphonates; Pharmacovigilance; Pregnancy; Telbivudine; Tenofovir; Thymidine | 2014 |
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2014 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Tenofovir; Treatment Outcome | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Tenofovir | 2014 |
New therapeutic perspectives in HBV: when to stop NAs.
Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2014 |
An update on hepatitis B, D, and E viruses.
Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E; Humans; Interferon-alpha; Liver Cirrhosis; Liver Failure; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
Managing hepatitis B to prevent liver cancer: recent advances.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic; Guanine; Hepatitis B, Chronic; Humans; Immune Tolerance; Incidence; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Risk; Tenofovir | 2014 |
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
Topics: Adenine; Antiviral Agents; Disease Management; DNA, Viral; Drug Delivery Systems; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B, Chronic; Humans; Interferons; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Tenofovir; Viral Load | 2014 |
Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Safety; Tenofovir | 2014 |
Molecular diagnosis and treatment of drug-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Diagnostic Techniques; Mutation; Nucleic Acid Hybridization; Organophosphonates; Phenotype; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2014 |
Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
[Treatment of viral hepatitis in children].
Topics: Adenine; Adolescent; Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
Topics: Antiviral Agents; Chi-Square Distribution; Clinical Trials as Topic; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Odds Ratio; Patient Selection; Risk Factors; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Treating Immune-tolerant Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy; Hepatitis B, Chronic; Humans; Interferons; Nucleotides; Organophosphonates; Tenofovir | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Long-Term Care; Organophosphonates; Tenofovir; Treatment Outcome | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Long-Term Care; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Virus Replication | 2015 |
Antiviral therapies and prospects for a cure of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Disease Management; Disease Models, Animal; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Mice; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2015 |
The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.
Topics: Antiviral Agents; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Patient Safety; Renal Elimination; Risk Assessment; Tenofovir; Treatment Outcome; Virus Replication | 2015 |
Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B.
Topics: Antiviral Agents; Databases, Factual; Drug Administration Schedule; Emtricitabine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Odds Ratio; Tenofovir | 2015 |
The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Guanine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Immunization Schedule; Marmota; T-Lymphocytes; Tenofovir; Vaccines, DNA; Virus Replication | 2015 |
Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Tenofovir | 2016 |
Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Tenofovir; Treatment Outcome | 2016 |
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Interferon-alpha; Lamivudine; Molecular Targeted Therapy; Organophosphonates; Practice Guidelines as Topic; Seroconversion; Telbivudine; Tenofovir; Thymidine; Viral Envelope Proteins | 2017 |
[Management and treatment of patients with hepatitis B].
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2016 |
The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
Topics: Acute Kidney Injury; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hypophosphatemia; Liver Cirrhosis; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Safety; Sustained Virologic Response; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection-2017.
Topics: Antiviral Agents; Biomarkers; Clinical Trials as Topic; Drug Design; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Tenofovir | 2017 |
Management of Antiviral Resistance in Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
Topics: Adenine; Antiviral Agents; Case Management; DNA, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; United States | 2008 |
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Multicenter Studies as Topic; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2008 |
[Resistance in hepatitis B virus].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Molecular; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication | 2008 |
[Clinical management of patients with chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Liver Transplantation; Male; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2008 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2009 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2008 |
Tenofovir for the treatment of hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Interactions; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Tenofovir disoproxil fumarate: in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Hepatitis B, Chronic; Humans; Organophosphonates; Prodrugs; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
Topics: Adenine; Adjuvants, Immunologic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Risk Assessment; Serologic Tests; Severity of Illness Index; Tenofovir; Treatment Outcome | 2010 |
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B.
Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2010 |
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphamide; Fatal Outcome; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunologic Factors; Immunotherapy; Liver Failure; Lymphoma, B-Cell, Marginal Zone; Male; Organophosphonates; Prednisone; Recurrence; Rituximab; Tenofovir; Vincristine; Virus Activation | 2010 |
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Organophosphonates; Quality of Life; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom | 2010 |
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2010 |
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2010 |
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Hepatitis B virus; Hepatitis B, Chronic; Humans; Multicenter Studies as Topic; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2010 |
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
Topics: Adenine; Antiviral Agents; Decision Making; Guanine; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon alpha-2; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Tenofovir; Treatment Outcome | 2011 |
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2011 |
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Hepatitis B virus resistance to antiviral drugs: where are we going?
Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Internalization; Virus Replication | 2011 |
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
Topics: Adenine; Antiviral Agents; Biomarkers; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Viral Load | 2012 |
Emerging pipeline drugs for hepatitis B infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Design; Drugs, Investigational; Guanine; Hepatitis B Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Interferons; Liver Cirrhosis; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Tenofovir | 2012 |
New perspectives in the therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Organophosphonates; Polymorphism, Genetic; Prognosis; Tenofovir | 2012 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2012 |
First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
Topics: Adenine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Life Style; Organophosphonates; Severity of Illness Index; Telbivudine; Tenofovir; Thymidine; Time Factors | 2012 |
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Mutation; Nucleosides; Nucleotides; Organophosphonates; Prognosis; Tenofovir; Viral Load | 2012 |
Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Models, Economic; Organophosphonates; Reproducibility of Results; Tenofovir | 2013 |
Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2013 |
Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine | 2004 |
New treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
[Liver transplantation for complications of hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Mutation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vaccination; Viral Load; Virus Replication | 2006 |
Personal view: the management of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Tenofovir | 2006 |
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Dogs; Drug Design; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Nucleotides; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2007 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
136 trial(s) available for tenofovir and Chronic Hepatitis B
| Article | Year |
|---|---|
Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphorus Compounds; Prodrugs; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cross-Over Studies; DNA, Circular; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Male; Nucleic Acids; Polymers; RNA, Viral; Seroconversion; Tenofovir; Treatment Outcome; Virus Inactivation | 2021 |
Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver f
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2021 |
Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2022 |
Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; RNA; Tenofovir; Treatment Outcome; Viral Load; Viremia; Virus Integration; Virus Replication | 2022 |
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Dyslipidemias; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Male; Middle Aged; Tenofovir | 2022 |
A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
Topics: Antiviral Agents; DNA, Viral; Hepatic Insufficiency; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Male; Middle Aged; Nucleosides; Tenofovir | 2022 |
Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized contro
Topics: Antiviral Agents; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir; Treatment Outcome | 2022 |
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.
Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Fumarates; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; RNA; Tenofovir; Treatment Outcome | 2023 |
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Polyethylene Glycols; Tenofovir; Treatment Outcome | 2023 |
Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Tenofovir; Treatment Outcome | 2023 |
Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Rituximab; Symptom Flare Up; Tenofovir | 2023 |
The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.
Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Double-Blind Method; Drug Administration Schedule; Drug Compounding; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Young Adult | 2019 |
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Combinations; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; RNA, Small Interfering; RNAi Therapeutics; Tenofovir; Time Factors; Young Adult | 2020 |
Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Prodrugs; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
Topics: Adenine; Adiposity; Antiviral Agents; Cross-Sectional Studies; DNA, Mitochondrial; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Organophosphonates; RNA, Mitochondrial; Tenofovir | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug Substitution; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nasopharyngitis; Renal Insufficiency; Respiratory Tract Infections; Sustained Virologic Response; Tenofovir | 2020 |
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Moldova; Nucleic Acids; Polyethylene Glycols; Polymers; Recombinant Proteins; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2020 |
Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Nucleosides; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Withholding Treatment | 2020 |
Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Topics: Adult; Antiviral Agents; Bone Density; Double-Blind Method; Drug Administration Schedule; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Republic of Korea; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Seroconversion; Sustained Virologic Response; Tenofovir; Time Factors | 2020 |
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Sustained Virologic Response; Telbivudine; Tenofovir | 2020 |
Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.
Topics: Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Tenofovir; Viral Load | 2021 |
A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.
Topics: Antiviral Agents; DNA, Viral; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Iran; Polyethylene Glycols; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction.
Topics: Antiviral Agents; Drug Tapering; Female; Hepatitis B, Chronic; Humans; Infant, Newborn; Kidney Diseases; Male; Tenofovir; Thailand | 2021 |
Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; Time Factors | 2021 |
Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial.
Topics: Adult; Aged; Alanine Transaminase; Biomarkers; Double-Blind Method; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebo Effect; Taiwan; Tenofovir; Treatment Outcome | 2021 |
Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Mothers; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
Topics: Adolescent; Adult; Alanine; Antiviral Agents; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2021 |
Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use.
Topics: Absorptiometry, Photon; Adult; Anti-Retroviral Agents; Body Composition; Bone Density; Bone Resorption; Cross-Sectional Studies; Female; Femur Neck; Fibroblast Growth Factor-23; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hip; Humans; Lamivudine; Lumbar Vertebrae; Male; Middle Aged; Osteoclasts; Tenofovir | 2021 |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; China; Cohort Studies; DNA, Viral; Fatty Liver; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Tenofovir; Treatment Outcome; Viremia | 2021 |
Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon version.
Topics: Adolescent; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adenine; Adult; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2021 |
Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Topics: Alanine; Antiviral Agents; Female; Fumarates; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Topics: Adult; Antiviral Agents; China; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Netherlands; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2018 |
Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Intention to Treat Analysis; Interferon-alpha; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir; Viral Load; Young Adult | 2017 |
Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine Transaminase; Antiviral Agents; Biomarkers; Cohort Studies; Coinfection; Ethiopia; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load; Young Adult | 2017 |
Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients.
Topics: Adult; Antiviral Agents; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B, Chronic; Hong Kong; Humans; Immunocompetence; Male; Middle Aged; Recurrence; Tenofovir; Young Adult | 2018 |
Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Nucleosides; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2018 |
Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study.
Topics: Adult; Aged; Antiviral Agents; Flow Cytometry; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Sustained Virologic Response; T-Lymphocyte Subsets; Tenofovir; Treatment Outcome | 2018 |
Tenofovir
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hospital Costs; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2017 |
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir; Young Adult | 2018 |
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
Topics: Adult; Aged; Antiviral Agents; Cytokines; DNA, Viral; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pteridines; Seroconversion; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.
Topics: Administration, Oral; Adult; Antiviral Agents; Area Under Curve; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Tenofovir; Viral Load | 2018 |
Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads.
Topics: Adult; Case-Control Studies; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Topics: Absorptiometry, Photon; Adult; Alanine Transaminase; Antiviral Agents; Bone Density; Bone Diseases, Metabolic; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hip; Humans; Lumbar Vertebrae; Male; Maleates; Middle Aged; Organophosphonates; Osteoporosis; Renal Insufficiency; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia.
Topics: Adolescent; Adult; Antiviral Agents; Biomarkers; Ethiopia; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Tenofovir; Treatment Adherence and Compliance; Treatment Outcome; Viral Load; Young Adult | 2018 |
Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immune Tolerance; Male; Preconception Care; Reproductive Techniques, Assisted; Seroconversion; Telbivudine; Tenofovir; Viral Load | 2019 |
Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Tenofovir; Treatment Outcome | 2019 |
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipase; Liver; Male; Middle Aged; Nucleotides; Reverse Transcriptase Inhibitors; Symptom Flare Up; Tenofovir; Withholding Treatment | 2019 |
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; CD8-Positive T-Lymphocytes; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Interferon-gamma; Interleukin-2; Male; Middle Aged; Tenofovir; Trans-Activators; Tumor Necrosis Factor-alpha; Viral Load; Viral Regulatory and Accessory Proteins; Young Adult | 2019 |
Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; Double-Blind Method; Female; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Tenofovir; Viral Load; Young Adult | 2019 |
Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
Topics: Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2019 |
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Internationality; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2019 |
Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Epitope Mapping; Epitopes; Female; Genotype; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Seroconversion; Tenofovir; Viral Load | 2019 |
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B, Chronic; Humans; Immunoglobulins; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; United States | 2013 |
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Evolution, Molecular; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phylogeny; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Failure; Young Adult | 2013 |
Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.
Topics: Adenine; Adult; Anti-Infective Agents, Local; Antiviral Agents; Carrier State; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2013 |
Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients.
Topics: Adenine; Adult; Antiviral Agents; B-Lymphocytes; Female; Flow Cytometry; Hepatitis B, Chronic; Homeostasis; Humans; Liver Diseases; Male; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2013 |
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viremia | 2014 |
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Europe; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; New Zealand; North America; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
Topics: Adenine; Adolescent; Adult; Asian; Creatinine; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Residence Characteristics; Tenofovir; Treatment Outcome; Young Adult | 2014 |
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Viremia; Virus Replication | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2014 |
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Point Mutation; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir | 2014 |
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Regression Analysis; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2014 |
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2015 |
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian or Other Pacific Islander; Organophosphonates; Statistics, Nonparametric; Tenofovir; Viral Load | 2015 |
Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Creatinine; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.
Topics: Adult; Antiviral Agents; Disease Transmission, Infectious; DNA, Viral; Female; Genetic Variation; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Tenofovir | 2015 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Tenofovir; Treatment Failure | 2016 |
Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.
Topics: Adult; Antiviral Agents; Creatinine; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2015 |
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Time Factors; Viral Load | 2015 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Republic of Korea; Tenofovir; Treatment Outcome | 2016 |
Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus.
Topics: Adenine; Adult; DNA, Viral; Female; Follow-Up Studies; Gestational Age; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Maternal Age; Multivariate Analysis; Organophosphonates; Patient Selection; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Reference Values; Risk Assessment; Taiwan; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aspartate Aminotransferases; Coinfection; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Prospective Studies; Tenofovir; Viral Load | 2015 |
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Time Factors; Treatment Outcome; Vitamin B Deficiency; Vitamin D; Vitamins; Young Adult | 2015 |
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Double-Blind Method; Drug Administration Schedule; Female; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Assessment; Tenofovir | 2015 |
Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Topics: Adenine; Adult; Amantadine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; RNA, Viral; Tenofovir; Virion | 2016 |
[Therapy discontinuation after many years of virus suppression is possible].
Topics: Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2015 |
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Internationality; Kaplan-Meier Estimate; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Risk Assessment; Severity of Illness Index; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2016 |
Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Republic of Korea; Tenofovir; Treatment Outcome | 2016 |
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.
Topics: Adult; Alanine Transaminase; Antiviral Agents; China; Congenital Abnormalities; Creatine Kinase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Intention to Treat Analysis; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Tenofovir; Viral Load; Young Adult | 2016 |
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Promoter Regions, Genetic; Sequence Analysis, DNA; Seroconversion; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Topics: Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Topics: Administration, Oral; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Tenofovir; Treatment Outcome | 2016 |
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Biopsy; Clinical Trials, Phase III as Topic; Fatty Liver; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Histocytochemistry; Humans; Liver; Male; Middle Aged; Tenofovir; Young Adult | 2017 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2008 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Mutation; Organophosphonates; Tenofovir | 2010 |
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Virus Replication | 2010 |
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Thailand | 2010 |
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2011 |
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricitabine; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2011 |
Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; India; Liver Failure, Acute; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Topics: Adenine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Gene Products, pol; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir | 2011 |
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Europe; Follow-Up Studies; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2011 |
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
Topics: Adenine; Adolescent; Alanine Transaminase; Antiviral Agents; Bone Density; Child; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir; Viral Load | 2012 |
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genome, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Safety Management; Severity of Illness Index; Tenofovir; Time Factors; Treatment Outcome | 2013 |
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Tolerance; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phenotype; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2012 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2013 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Tenofovir; Time Factors; Viral Load | 2002 |
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Tenofovir in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Models, Biological; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Tenofovir; Treatment Failure | 2006 |
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2006 |
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2006 |
Second tenofovir phase III study for the chronic HBV reaches primary endpoint.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Thailand; Transaminases; Treatment Outcome; Viral Load | 2008 |
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2008 |
700 other study(ies) available for tenofovir and Chronic Hepatitis B
| Article | Year |
|---|---|
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidine Nucleosides; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2007 |
Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
Topics: Coinfection; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Prospective Studies; Tenofovir | 2021 |
Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B.
Topics: Antiviral Agents; Fibrosis; Guanine; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Concentration of LDLR, degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate.
Topics: Adult; Aged; Antiviral Agents; Fatty Liver; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins, HDL; Liver Cirrhosis; Male; Middle Aged; Receptors, LDL; Tenofovir; Triglycerides | 2021 |
Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Meta-Analysis as Topic; Proportional Hazards Models; Research Design; Risk Assessment; Tenofovir; Treatment Outcome | 2022 |
Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Tenofovir | 2021 |
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs.
Topics: Aged; Cohort Studies; Female; Hepatitis B, Chronic; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nucleosides; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Artificial Intelligence; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Computer Simulation; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Tenofovir; White People | 2022 |
Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Cohort Studies; COVID-19; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Odds Ratio; Republic of Korea; Risk; Severity of Illness Index; Tenofovir; Young Adult | 2021 |
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2022 |
Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Tenofovir; Treatment Outcome | 2022 |
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T-cell recognition of infected HepG2-NTCP.
Topics: CD8-Positive T-Lymphocytes; Culture Media, Conditioned; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon Type I; RNA Interference; Tenofovir; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2022 |
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Topics: Adult; Age Factors; Antiviral Agents; Asian People; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Race Factors; Recurrence; Retreatment; Tenofovir; White People | 2022 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Topics: Aged; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir; Treatment Outcome | 2021 |
Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
Topics: Acute-On-Chronic Liver Failure; Adult; Antiviral Agents; COVID-19; DNA, Viral; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; SARS-CoV-2; Tenofovir; Treatment Outcome | 2022 |
Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Tenofovir; Treatment Failure; Treatment Outcome; Young Adult | 2022 |
Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
Topics: Adenine; Adult; Antiviral Agents; China; Cleft Lip; Cleft Palate; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Pregnancy; Pregnant Women; Prospective Studies; Tenofovir | 2022 |
Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Symptom Flare Up; Tenofovir; Treatment Outcome | 2022 |
Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir | 2021 |
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Topics: Adenine; Alanine; Cholesterol; Hepatitis B, Chronic; Humans; Propensity Score; Tenofovir | 2022 |
Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Bone Density; Guanine; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
[Clinical significance and management strategies of low-level viremia during the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viremia | 2021 |
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Kidney; Liver Transplantation; Tenofovir; Treatment Outcome | 2023 |
Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2022 |
Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Topics: Aged; Alanine; Antiviral Agents; Drug Substitution; Female; Follow-Up Studies; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.
Topics: Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Risk Factors; Tenofovir | 2022 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2022 |
First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Prospective Studies; Retrospective Studies; Tenofovir; United States | 2022 |
Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Radiofrequency Ablation; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Topics: Adult; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseases; Liver Transplantation; Registries; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Prognosis; Taiwan; Tenofovir; Treatment Outcome | 2022 |
Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir; Viremia | 2022 |
Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus.
Topics: Antiviral Agents; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pregnancy; Pregnant Women; Symptom Flare Up; Tenofovir; Viral Load | 2022 |
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Milk, Human; Pregnancy; Tenofovir | 2022 |
Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D.
Topics: DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2022 |
Primary partial response with tenofovir monotherapy: two adults and one child.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study.
Topics: Antiviral Agents; Cohort Studies; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Tenofovir; Treatment Outcome | 2022 |
Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studies; Tenofovir | 2022 |
Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Recurrence; Tenofovir; Treatment Outcome | 2022 |
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Treatment of chronic hepatitis B: virological and pharmacological aspects
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients.
Topics: Antiviral Agents; Glucose; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Retrospective Studies; Tenofovir; Treatment Outcome; Uric Acid | 2022 |
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pregnancy; Pregnant Women; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human; Mothers; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Human; Mothers; Tenofovir | 2022 |
Comparison of tenofovir disoproxil fumarate and telbivudine in preventing hepatitis B transmission in mothers with high viral load.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Telbivudine; Tenofovir; Viral Load | 2023 |
Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Tenofovir; Treatment Outcome | 2022 |
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Tenofovir | 2022 |
Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: A cohort study.
Topics: Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Viral Load | 2022 |
Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2023 |
Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Symptom Flare Up; Tenofovir; Treatment Outcome; Withholding Treatment | 2022 |
Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?
Topics: Adult; Antiviral Agents; DNA, Viral; Fatty Liver; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Awareness and treatment of chronic hepatitis B in Malaysia-findings from a community-based screening campaign.
Topics: Adult; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Malaysia; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Maleates; Organophosphonates; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Recurrence; Retreatment; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.
Topics: Antiviral Agents; Cohort Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis A; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Tenofovir; Viral Load | 2023 |
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection.
Topics: Cohort Studies; Coinfection; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Tenofovir; Viral Load | 2023 |
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Fumarates; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Efficacy and Safety of Peginterferon
Topics: Antiviral Agents; Genotype; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2022 |
Treating Hepatitis B Virus in Times of COVID-19: The Case for Clinical Pharmacogenomics Research in Tenofovir-Induced Kidney Toxicity.
Topics: Antiviral Agents; COVID-19; DNA, Viral; Ecosystem; Ghana; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Pharmacogenetics; SARS-CoV-2; Tenofovir | 2022 |
Prospective cohort study of prevention of mother to child transmission of hepatitis B infection and 9 months follow-up of hepatitis B-exposed infants at Ile-Ife, Nigeria.
Topics: Adult; DNA, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nigeria; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Tenofovir | 2022 |
Pembrolizumab-induced acute exacerbation of hepatitis D.
Topics: Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; RNA; Tenofovir | 2023 |
Long-Acting Treatments for Hepatitis B.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Genotype; Haplotypes; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Tenofovir | 2023 |
Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome; Withholding Treatment | 2023 |
Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Hepatitis B, Chronic; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Postpartum Period; Pregnancy; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs.
Topics: Antiviral Agents; China; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prevalence; Tenofovir; Treatment Outcome; Viremia | 2023 |
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2023 |
Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; T-Lymphocytes, Regulatory; Tenofovir; Treatment Outcome; Viral Load | 2023 |
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Alanine Transaminase; Antiviral Agents; Cyclophosphamide; DNA, Viral; Doxorubicin; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prospective Studies; Rituximab; Tenofovir; Vincristine | 2023 |
Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; COVID-19; Hepatitis B, Chronic; Humans; Retrospective Studies; SARS-CoV-2; Tenofovir; Treatment Outcome | 2023 |
Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Risk Factors; Tenofovir | 2023 |
Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Treatment Failure; Vietnam | 2023 |
Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-18; Interleukin-7; Recurrence; Tenofovir; Treatment Outcome | 2023 |
Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study.
Topics: Antiviral Agents; Artificial Intelligence; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Machine Learning; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Tenofovir; Treatment Outcome | 2023 |
Viral hepatitis in persons living with HIV in the post-COVID era.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; COVID-19; Drug Users; Hepatitis A; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Sexual and Gender Minorities; Substance Abuse, Intravenous; Tenofovir | 2023 |
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Transplantation; Retrospective Studies; Tenofovir | 2023 |
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Kidney; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Interleukin-1beta; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Prospective Studies; Tenofovir; Treatment Outcome | 2023 |
Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Association of Alanine Aminotransferase Flares to Hepatitis B Surface Decline During Tenofovir Alone or With Pegylated Interferon Alfa.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Tenofovir | 2023 |
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study.
Topics: Antiviral Agents; DNA, Viral; Elasticity Imaging Techniques; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2023 |
Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
Topics: Aldo-Keto Reductase Family 1 member B10; Aldo-Keto Reductases; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Tenofovir | 2023 |
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2023 |
Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Tenofovir; Treatment Outcome | 2023 |
Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Retrospective Studies; Risk Factors; Tenofovir; Treatment Outcome | 2023 |
Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea.
Topics: Adenine; Adult; Alanine; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Osteoporotic Fractures; Retrospective Studies; Tenofovir | 2023 |
Study of the Molecular Dynamics Stability in the Inhibitory Interaction of Tenofovir Disoproxil Fumarate against CTLA-4 in Chronic Hepatitis B Patients.
Topics: CTLA-4 Antigen; Hepatitis B, Chronic; Humans; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Tenofovir | 2023 |
Severe skeletal damage suggesting neoplastic disease as a manifestation of tenofovir-induced Fanconi syndrome in chronic hepatitis B.
Topics: Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Neoplasms; Tenofovir | 2023 |
Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy-Author's reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins; Liver Neoplasms; Tenofovir; Treatment Outcome | 2023 |
Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins; Liver Neoplasms; Tenofovir; Treatment Outcome | 2023 |
Five-year results of a treatment program for chronic hepatitis B in Ethiopia.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Ethiopia; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir | 2023 |
Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Tenofovir; Treatment Outcome | 2023 |
Successful results of early nucleos(t)ide analogue treatment for liver transplantation candidates with severe acute hepatitis B infection.
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure, Acute; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2024 |
The relationship between the use of nucleos(t)ide analogs and metabolic parameters in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Glycated Hemoglobin; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Tenofovir; Treatment Outcome | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |
Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B.
Topics: Antiviral Agents; COVID-19; Hepatitis B, Chronic; Humans; Incidence; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Nucleosides; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins | 2019 |
Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis.
Topics: Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Meta-Analysis as Topic; Systematic Reviews as Topic; Tenofovir | 2019 |
Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting.
Topics: Adult; Antiviral Agents; Costs and Cost Analysis; Disease Management; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2020 |
Editorial: tenofovir disoproxil fumarate and prevention of mother-to-child transmission of hepatitis B virus-authors' reply.
Topics: Child; Female; Hemochromatosis; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Infectious Disease Transmission, Vertical; Mothers; Tenofovir; Viremia | 2019 |
Editorial: tenofovir disoproxil fumarate and prevention of mother-to-child transmission of hepatitis B virus.
Topics: Child; Female; Hemochromatosis; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Infectious Disease Transmission, Vertical; Mothers; Tenofovir; Viremia | 2019 |
Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins | 2020 |
Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Survival Analysis; Tenofovir; Treatment Outcome | 2019 |
Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon-alpha; Interleukin-10; Interleukin-12; Lamivudine; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Nucleosides; Organophosphonates; Proto-Oncogene Proteins c-akt; Tenofovir | 2020 |
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
Topics: Adult; DNA Mutational Analysis; DNA Probes; DNA, Viral; Drug Resistance, Viral; Feasibility Studies; Female; Gene Products, pol; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Oligonucleotides; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir | 2019 |
In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir | 2019 |
First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China.
Topics: Antiviral Agents; Cost-Benefit Analysis; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; Tenofovir | 2019 |
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Topics: Adult; Aftercare; Antiviral Agents; Carcinoma, Hepatocellular; China; Disease Progression; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Retreatment; Retrospective Studies; Taiwan; Tenofovir; Treatment Outcome; Withholding Treatment | 2019 |
Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients."
Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir | 2019 |
Letter: decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers.
Topics: Child; Female; Hemochromatosis; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Mothers; Tenofovir; Viremia | 2019 |
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2019 |
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Cohort Studies; Disease Progression; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; International Cooperation; Japan; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Taiwan; Tenofovir; Treatment Outcome; United States | 2020 |
Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis".
Topics: Carcinoma, Hepatocellular; Delayed Diagnosis; Hepatitis B, Chronic; Humans; Liver Neoplasms; Mutation; Tenofovir | 2019 |
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Propensity Score; Republic of Korea; Risk; Tenofovir | 2020 |
Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
Topics: Antiviral Agents; Canada; Cost-Benefit Analysis; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Probability; Quality-Adjusted Life Years; Tenofovir; Treatment Outcome | 2020 |
Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Predictive Value of Tests; Retrospective Studies; RNA; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Comments on 'Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance'.
Topics: Guanine; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2020 |
Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Reply to: "Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea".
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prognosis; Republic of Korea; Tenofovir | 2020 |
Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea.
Topics: Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Surveys and Questionnaires; Tenofovir; Transaminases; Treatment Outcome | 2020 |
Response to comments on: Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Topics: Guanine; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2020 |
Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Propensity Score; Republic of Korea; Tenofovir | 2020 |
Tenofovir for the Prevention of HCC in Patients With Cirrhosis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir | 2020 |
Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate.
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Hypophosphatemia; Male; Middle Aged; Republic of Korea; Retrospective Studies; Risk Factors; Tenofovir; Treatment Outcome | 2019 |
Placental infection of hepatitis B virus among Thai pregnant women: Clinical risk factors and its association with fetal infection.
Topics: Adult; Cohort Studies; Female; Fetal Diseases; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Placenta Diseases; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Risk Factors; Tenofovir; Thailand; Viral Load | 2020 |
Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Serologic Tests; Tenofovir | 2020 |
Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Liver Function Tests; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Severity of Illness Index; Tenofovir | 2020 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Risk; Tenofovir; Treatment Outcome | 2020 |
The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B.
Topics: Antiviral Agents; Cesarean Section; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Tenofovir; Viral Load | 2020 |
Inhibitory Effect of Nucleos(t)ide Analogs on Telomerase Activity and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Telomerase; Tenofovir | 2020 |
The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Child; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Japan; Male; Mothers; Pregnancy; Pregnancy Complications; Prenatal Care; Tenofovir; Viral Load | 2020 |
Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Tenofovir | 2020 |
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Nucleotides; Platelet Count; Research Design; Risk; Tenofovir; Time Factors | 2020 |
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; Treatment Outcome; White People; Young Adult | 2020 |
Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver; Liver Neoplasms; Male; Middle Aged; Molecular Typing; Republic of Korea; Risk Adjustment; Risk Factors; Tenofovir; Time Factors | 2020 |
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Topics: Antiviral Agents; Drug Substitution; Guanine; Hepatitis B, Chronic; Humans; Medication Adherence; Patient Satisfaction; Retrospective Studies; Surveys and Questionnaires; Tenofovir | 2020 |
Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Blood Platelets; Female; Guanine; Hepatitis B, Chronic; Humans; Liver; Liver Cirrhosis; Male; Mean Platelet Volume; Middle Aged; Platelet Count; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2020 |
Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
Topics: Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Research Design; Retrospective Studies; Serum Albumin; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Propensity Score; Republic of Korea; Tenofovir | 2020 |
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2020 |
[Evaluation of Histological Response in Chronic Hepatitis B Patients with Tenofovir or Entecavir Therapy].
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2020 |
Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Elasticity Imaging Techniques; Female; Guanine; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Liver; Male; Prospective Studies; Seroconversion; Telbivudine; Tenofovir | 2020 |
Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Tenofovir | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
Topics: Adenine; Alanine; Antiviral Agents; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipid Metabolism; Risk Assessment; Tenofovir | 2020 |
Approach to women who become pregnant while on tenofovir disoproxil fumarate for chronic B hepatitis: A report of two cases.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Tenofovir | 2020 |
No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Long-Term Effects of Tenofovir on Liver Histopathology in Patients with Chronic Viral Hepatitis B Infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Liver; Male; Middle Aged; Seroconversion; Tenofovir; Time; Young Adult | 2020 |
Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Retrospective Studies; Risk; Tenofovir | 2020 |
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Sustained Virologic Response; Tenofovir | 2020 |
No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tenofovir | 2021 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
Topics: Antiviral Agents; Guanine; Hepatitis Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Transplantation; Tenofovir; Treatment Outcome | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Young Adult | 2020 |
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Follow-Up Studies; Guanine; Hepatectomy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Tenofovir | 2021 |
Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Topics: Antiviral Agents; DNA, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Topics: Antigens, Surface; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Recurrence; Tenofovir; Treatment Outcome | 2020 |
Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Kidney Function Tests; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
Topics: Acute Kidney Injury; Antiviral Agents; Ascites; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir | 2020 |
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antiviral Agents; DNA, Viral; Female; Guanine; Hematologic Neoplasms; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Tenofovir; Viral Load; Virus Activation; Withholding Treatment; Young Adult | 2020 |
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Risk Assessment; Tenofovir; White People | 2020 |
High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis.
Topics: Antiviral Agents; Body Mass Index; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Tenofovir; Treatment Outcome | 2020 |
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis.
Topics: Antiviral Agents; China; Databases, Factual; DNA Viruses; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Function Tests; Male; Meta-Analysis as Topic; Nucleosides; Quality of Life; Randomized Controlled Trials as Topic; Systematic Review as Topic; Tenofovir | 2020 |
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir | 2020 |
Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; South Africa; Tenofovir; Treatment Outcome | 2020 |
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Japan; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2020 |
Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
Topics: Anti-HIV Agents; Australia; Coinfection; DNA, Viral; Drug Administration Schedule; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; RNA, Viral; Tenofovir; Thailand | 2020 |
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Tenofovir | 2020 |
Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2020 |
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Doxorubicin; End Stage Liver Disease; Ethiodized Oil; Ethiopia; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Hepatectomy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2020 |
Tooth loss associated with the use of tenofovir disoproxil fumarate.
Topics: Adult; Antiviral Agents; Asian People; Hepatitis B, Chronic; Humans; Male; Tenofovir; Tooth Loss | 2020 |
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Male; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment-still an open issue.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir | 2020 |
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues.
Topics: Guanine; Hepatitis B, Chronic; Humans; Pharmaceutical Preparations; Tenofovir | 2020 |
Rely to: 'Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues'.
Topics: Guanine; Hepatitis B, Chronic; Humans; Pharmaceutical Preparations; Tenofovir | 2021 |
Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Renal Dialysis; Tenofovir; Treatment Outcome | 2021 |
Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy.
Topics: Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Myanmar; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Thailand; Viral Load | 2020 |
Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Infant, Newborn; Liver Neoplasms; Male; Retrospective Studies; Tenofovir | 2021 |
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Nucleotides; Tenofovir | 2020 |
Real-world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate-treated chronic hepatitis B pregnant patients in North America.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Male; North America; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Tenofovir | 2020 |
Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Taiwan; Tenofovir | 2020 |
Is urinary β2-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy?
Topics: Adult; Antiviral Agents; Biomarkers; Creatinine; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Diseases; Male; Tenofovir | 2021 |
Melatonin protects against tenofovir-induced nephrotoxicity in rats by targeting multiple cellular pathways.
Topics: Animals; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Male; Melatonin; Metabolic Networks and Pathways; Models, Animal; Rats; Renal Insufficiency; Tenofovir | 2021 |
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome | 2021 |
Optimization of the algorithm diagnosis chronic hepatitis B markers in patients with newly diagnosed HIV infection.
Topics: Algorithms; DNA, Viral; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Tenofovir | 2020 |
Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B.
Topics: Alanine; Alanine Transaminase; Antiviral Agents; Diabetes Mellitus; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Topics: Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Tenofovir; Viral Load | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome; Viremia | 2021 |
The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
Topics: Acute-On-Chronic Liver Failure; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2021 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2021 |
Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Tenofovir; Treatment Outcome | 2021 |
Debate settled for elevated alanine aminotransferase in hepatitis B?
Topics: Alanine Transaminase; Double-Blind Method; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2021 |
Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Viral; Female; Genes, Viral; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Liver Neoplasms; Middle Aged; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins; Virus Replication | 2021 |
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Europe; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Europe; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir; Viral Load; Virus Replication | 2021 |
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.
Topics: Adult; Antiviral Agents; Female; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2021 |
Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
Topics: Adult; Aged; Alanine; Antiviral Agents; Asian; Black or African American; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mortality; Propensity Score; Proportional Hazards Models; Retrospective Studies; Safety-net Providers; Tenofovir; United States; Urban Population; White People | 2021 |
Another oral antiviral treatment, but still far away from hepatitis B virus cure.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Maleates; Organophosphonates; Tenofovir | 2021 |
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Topics: Adult; Aged; Alanine; Alanine Transaminase; DNA, Viral; Drug Substitution; Female; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver; Liver Function Tests; Male; Middle Aged; Prodrugs; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Tenofovir | 2021 |
Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy.
Topics: Adult; Antiviral Agents; Bone Density; Child, Preschool; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Male; Nucleosides; Pregnancy; Retrospective Studies; Telbivudine; Tenofovir | 2021 |
A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; North America; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Topics: Alanine; Canada; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2021 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
The partial virological response to Tenofovir monotherapy in naive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2021 |
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Taiwan; Tenofovir | 2021 |
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Taiwan; Tenofovir | 2021 |
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Tenofovir; Young Adult | 2021 |
Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil.
Topics: Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Mothers; Tenofovir | 2022 |
Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Tenofovir-induced osteomalacia with hypophosphataemia.
Topics: Antiviral Agents; Fanconi Syndrome; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Osteomalacia; Tenofovir | 2021 |
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
Topics: Antiviral Agents; Biomarkers; Comorbidity; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
Peginterferon alfa-2b combined with tenofovir disoproxil fumarate induced high clinical cure rate in inactive chronic hepatitis B virus carriers.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2021 |
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Pharmaceutical Preparations; Tenofovir; Treatment Outcome | 2021 |
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy.
Topics: Antiviral Agents; Fibrosis; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2021 |
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy - Authors' reply.
Topics: Fibrosis; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Tenofovir | 2021 |
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; United Kingdom; Viral Load; Young Adult | 2021 |
Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Tenofovir; Turkey | 2021 |
Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Pharmaceutical Preparations; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2021 |
Plasma and Breast Milk Pharmacokinetics of Tenofovir Disoproxil Fumarate in Nursing Mother with Chronic Hepatitis B-Infant Pairs.
Topics: Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infant; Milk, Human; Mothers; Pharmaceutical Preparations; Pregnancy; Tenofovir; Viral Load | 2021 |
Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Logistic Models; Male; Multivariate Analysis; Retrospective Studies; ROC Curve; Tenofovir | 2021 |
Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy.
Topics: Adult; Antiviral Agents; Breast Feeding; China; Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Nucleosides; Patient Compliance; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir | 2021 |
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir | 2021 |
Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Topics: Adenine; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Genetic; RNA-Directed DNA Polymerase; Sequence Analysis; Tenofovir; Treatment Failure | 2017 |
Recovery of NK(CD56+CD3-) Cells after One Year of Tenofovir Therapy for Chronic Hepatitis B Infection.
Topics: Adult; Aged; Antiviral Agents; CD3 Complex; CD56 Antigen; Cell Count; DNA, Viral; Female; GPI-Linked Proteins; Hepatitis B, Chronic; Humans; Killer Cells, Natural; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily C; Receptors, IgG; Tenofovir; Time Factors | 2017 |
Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Republic of Korea; Severity of Illness Index; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2017 |
Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
Topics: Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Gene Products, pol; Genes, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Selection, Genetic; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2017 |
Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir | 2017 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide for hepatitis B: evolution or revolution?
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2016 |
Occult hepatitis B infection reactivation after ruxolitinib therapy.
Topics: Aged; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanine; Hepatitis B, Chronic; Humans; Hydroxyurea; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Tenofovir; Virus Activation | 2017 |
Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir.
Topics: Adult; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Models, Theoretical; Risk Assessment; Tenofovir | 2017 |
Is tenofovir the answer to further preventing mother-to-child transmission of hepatitis B?
Topics: Antiviral Agents; Child; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Mothers; Tenofovir | 2016 |
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Practice Guidelines as Topic; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Europe; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; White People | 2017 |
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.
Topics: Antiviral Agents; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Seoul; Tenofovir; Treatment Outcome | 2017 |
Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
Topics: Alanine; Alanine Transaminase; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2017 |
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; ROC Curve; Tenofovir; Treatment Outcome | 2017 |
Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Republic of Korea; Tenofovir; Time Factors; Young Adult | 2017 |
Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.
Topics: Aged; Antiviral Agents; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Lipoproteins; Male; Middle Aged; Propensity Score; Retrospective Studies; Tenofovir; Treatment Outcome | 2017 |
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lactic Acid; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Sex Factors; Tenofovir; Time Factors; Treatment Outcome; Up-Regulation; Young Adult | 2017 |
A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Middle Aged; Nucleosides; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2018 |
Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus-authors' reply.
Topics: Child; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Tenofovir | 2017 |
Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus.
Topics: Child; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy Complications, Infectious; Tenofovir | 2017 |
Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nuclos(t)ides-Naïve Patients with Chronic Hepatitis B.
Topics: Adult; Biomarkers; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply.
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosphonates; Tenofovir | 2017 |
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed.
Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosphonates; Tenofovir | 2017 |
Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Polymerase Chain Reaction; Sensitivity and Specificity; Seroconversion; Tenofovir; Viral Load; Virus Replication | 2017 |
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2017 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Renal Dialysis; Tenofovir; Treatment Outcome | 2017 |
Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
Topics: Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2018 |
[Effect of clinical first-line Antiviral Agents on outcome of chronic hepatitis B treatment].
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2017 |
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome | 2018 |
Pathologic femoral fracture due to tenofovir-induced Fanconi syndrome in patient with chronic hepatitis B: A case report.
Topics: Antiviral Agents; Fanconi Syndrome; Femoral Fractures; Fractures, Spontaneous; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2017 |
Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Young Adult | 2017 |
Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adrenal Cortex Hormones; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Middle Aged; Tenofovir; Tomography, X-Ray Computed | 2018 |
Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Comorbidity; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Assessment; Sex Factors; Taiwan; Tenofovir | 2018 |
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Remission Induction; Retrospective Studies; Tenofovir | 2018 |
The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Assessment; Tenofovir | 2018 |
High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Topics: Adult; alpha-Fetoproteins; Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Female; Follow-Up Studies; Glycoproteins; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Research Design; Retrospective Studies; Sex Factors; Tenofovir | 2018 |
Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Tenofovir | 2018 |
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separation; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; T-Lymphocytes; Tenofovir | 2018 |
Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Antiviral Agents; Bone Density; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Parathyroid Hormone; Prospective Studies; Risk Assessment; Tenofovir; Vitamin D Deficiency; Young Adult | 2018 |
Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Secondary Prevention; Tenofovir; Treatment Outcome | 2018 |
Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients.
Topics: Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2018 |
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2018 |
Effect of tenofovir on renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Bilirubin; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Tenofovir | 2018 |
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Topics: Adult; Aged; Biomarkers; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Predictive Value of Tests; Recurrence; Secondary Prevention; Tenofovir; Time Factors | 2018 |
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Data Accuracy; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Research Design; Risk Assessment; Risk Factors; Taiwan; Tenofovir | 2018 |
Viral hepatitis: Maternal tenofovir use does not improve prevention of perinatal HBV transmission.
Topics: Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir | 2018 |
Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B.
Topics: Acidosis, Lactic; Antiviral Agents; DNA Polymerase gamma; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Male; Middle Aged; Rhabdomyolysis; Telbivudine; Tenofovir; Thymidine | 2018 |
Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection.
Topics: Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Liver Cirrhosis; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Virus Activation; Young Adult | 2019 |
Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study.
Topics: Administration, Oral; Antiviral Agents; Cross-Sectional Studies; Drug Costs; Financing, Government; Hepatitis B, Chronic; Humans; Ontario; Reimbursement Mechanisms; Tenofovir | 2018 |
Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
Topics: Adult; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Case-Control Studies; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Retrospective Studies; Severity of Illness Index; Tenofovir | 2018 |
Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2018 |
Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
Topics: Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Retrospective Studies; Telbivudine; Tenofovir; Young Adult | 2018 |
Monitoring and treatment results of 88 HBsAg-positive pregnant women.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Tenofovir; Young Adult | 2016 |
Causal Inference for Observational Studies.
Topics: Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Propensity Score; Tenofovir | 2019 |
Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Taiwan; Tenofovir | 2019 |
Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Korea; Liver Failure; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Survival Analysis; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Young Adult | 2019 |
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Topics: Adult; Aged; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retreatment; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Middle Aged; Registries; Renal Insufficiency, Chronic; Tenofovir; Treatment Outcome | 2018 |
Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biostatistics; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir | 2019 |
Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Nucleosides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Seroconversion; Tenofovir | 2018 |
Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome.
Topics: Antiviral Agents; Bone Density Conservation Agents; Denosumab; Fanconi Syndrome; Fractures, Stress; Hepatitis B, Chronic; Humans; Hypophosphatemia; Male; Middle Aged; Osteomalacia; Radiography; Radionuclide Imaging; Tenofovir; Tibial Fractures; Tomography, X-Ray Computed | 2019 |
Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon.
Topics: Adolescent; Adult; Antiviral Agents; Biomarkers; Cameroon; Female; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Patient Selection; Practice Guidelines as Topic; Tenofovir; Viral Load; Young Adult | 2018 |
Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
Topics: Antiviral Agents; Brazil; Coinfection; Disease Transmission, Infectious; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferons; Male; Models, Theoretical; Tenofovir; Viral Load | 2018 |
Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Protective Factors; Republic of Korea; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2019 |
Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2018 |
Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients.
Topics: Adult; Biomarkers; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2018 |
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Liver Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Retrospective Studies; Risk Assessment; Seroepidemiologic Studies; Sustained Virologic Response; Tenofovir | 2019 |
Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Male; Middle Aged; Nutrition Surveys; Organophosphonates; Retrospective Studies; Tenofovir | 2018 |
Genotype Matters in Patients with Acute-on-chronic Liver Failure Due to Reactivation of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Virus Activation; Young Adult | 2018 |
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Nucleosides; Nucleotides; Practice Patterns, Physicians'; Spain; Tenofovir; Transients and Migrants; Treatment Outcome; Viral Load | 2018 |
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Withholding Treatment | 2019 |
Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Tenofovir; Viral Load; Young Adult | 2019 |
Letter: chronic kidney disease risk in patients with chronic hepatitis B-authors' reply.
Topics: Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Tenofovir | 2018 |
Letter: chronic kidney disease risk in patients with chronic hepatitis B.
Topics: Guanine; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Tenofovir | 2018 |
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Tenofovir; Virus Activation; Young Adult | 2019 |
Prevention of Mother-to-Child Transmission in Patients with Chronic Hepatitis B Virus Infection and High Viral Loads
Topics: Antiviral Agents; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load | 2018 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pelvic Bones; Phosphorous Acids; Prospective Studies; Spine; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection.
Topics: Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
Topics: Fatty Liver; Guanine; Hepatitis B, Chronic; Humans; Tenofovir | 2019 |
Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Reproducibility of Results; Risk Assessment; Serum Albumin; Sex Factors; Tenofovir | 2019 |
Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea.
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Patient Safety; Prospective Studies; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2019 |
Tenofovir disoproxil fumarate may not cause renal and bone toxicity in chronic hepatitis B patients: a retrospective cross-sectional study
Topics: Antiviral Agents; Bone Density; Calcium; Cross-Sectional Studies; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Hypocalcemia; Hypophosphatemia; Phosphates; Retrospective Studies; Tenofovir | 2019 |
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Asian People; Bone Diseases, Metabolic; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2019 |
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Topics: Aged; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2019 |
Towards finite oral antiviral treatment for chronic hepatitis B.
Topics: Antiviral Agents; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2019 |
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2019 |
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2019 |
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Propensity Score; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Occult hepatitis B and HIV infection.
Topics: Anti-Retroviral Agents; Coinfection; DNA, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Virus Activation | 2019 |
[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].
Topics: Adenine; Alanine; Alkaline Phosphatase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fanconi Syndrome; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety.
Topics: Adult; Antiviral Agents; Fathers; Fertility; Fetus; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Male; Surveys and Questionnaires; Tenofovir; Viral Load | 2019 |
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Nucleotides; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2020 |
Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Black People; Deprescriptions; Disease Progression; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; North America; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Tenofovir; Viral Load | 2019 |
Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Body Mass Index; Ethiopia; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors; Survival Rate; Tenofovir; Time Factors; Young Adult | 2019 |
Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Telbivudine; Tenofovir; Time Factors; Treatment Outcome | 2019 |
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotyping Techniques; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Tenofovir; Young Adult | 2019 |
A case of entecavir-induced Fanconi syndrome.
Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B, Chronic; Humans; Hypokalemia; Hypophosphatemia; Male; Nucleosides; Tenofovir; Treatment Outcome; Withholding Treatment | 2019 |
Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
Topics: Adult; Antiviral Agents; Child; Cost-Benefit Analysis; Developing Countries; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Mass Screening; Models, Biological; Pregnancy; Pregnancy Complications, Infectious; South Africa; Tenofovir; Vaccination; Young Adult | 2019 |
Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2020 |
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir | 2020 |
In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
Topics: Activating Transcription Factor 4; Adenine; Antiviral Agents; Apoptosis; Caspase 12; Cell Line; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Epithelial Cells; Female; Glomerular Filtration Rate; Heat-Shock Proteins; Hepatitis A Virus Cellular Receptor 1; Hepatitis B, Chronic; Humans; In Vitro Techniques; Interleukin-18; Kidney Tubules; Lamivudine; Lipocalin-2; Male; Middle Aged; Organophosphonates; Prospective Studies; Protective Agents; Renal Insufficiency, Chronic; Severity of Illness Index; Telbivudine; Tenofovir | 2019 |
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Topics: Aged; Antiviral Agents; Coinfection; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Duration of Therapy; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Lipopeptides; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Patient Acuity; RNA, Viral; Tenofovir; Treatment Outcome | 2019 |
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Tenofovir; Young Adult | 2019 |
Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis.
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Tenofovir; Virus Replication | 2019 |
Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Telbivudine; Tenofovir; Thymidine; Viral Load | 2019 |
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Organophosphonates; Polyethylene Glycols; Precision Medicine; Prognosis; Quality-Adjusted Life Years; Recombinant Proteins; Tenofovir; Viral Load | 2013 |
[Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Models, Theoretical; Organophosphonates; Quality-Adjusted Life Years; Tenofovir | 2012 |
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Disease Management; DNA, Viral; Europe; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Geographic tongue and tenofovir.
Topics: Adenine; Glossitis, Benign Migratory; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Spain; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2013 |
Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; Creatinine; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Kidney; Male; Middle Aged; Organophosphonates; Phosphates; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2013 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
[HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
Topics: Adenine; Biopsy; Drug Resistance, Multiple, Viral; Female; Genes, pol; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Middle Aged; Mutation; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective.
Topics: Adenine; Adult; Aged; Bilirubin; Creatinine; DNA, Viral; Female; Hepatitis B, Chronic; Humans; India; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Platelet Count; Prospective Studies; Severity of Illness Index; Survival Analysis; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Comparison of tenofovir and entecavir in patients with chronic HBV infection.
Topics: Adenine; Adult; Aged; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Immunoglobulins; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome | 2014 |
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Europe; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hospitalization; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Monitoring, Ambulatory; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
Topics: Adenine; Adult; Antiviral Agents; California; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2014 |
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Interactive medical case: wasting away.
Topics: Adenine; Adult; Bone Density; Electrolytes; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; Hypokalemia; Nausea; Organophosphonates; Osteomalacia; Pain; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Host-Derived Cellular Factors; Humans; Interleukin-10; Lamivudine; Middle Aged; Mutation; Nucleosides; Organophosphonates; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Sex Factors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tenofovir; Viral Load | 2014 |
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Prospective Studies; Sensitivity and Specificity; Tenofovir; Viral Load | 2015 |
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Hungary; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2014 |
Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Severity of Illness Index; Tenofovir; Time Factors; Young Adult | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients--authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Drugs, Essential; Female; Health Services Research; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir; Thailand; Treatment Outcome | 2014 |
Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Young Adult | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir?
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Substitution; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Genetic Association Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Mutation, Missense; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Organophosphonates; Recombinant Proteins; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
Topics: Adenine; Adult; Cohort Studies; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Organophosphonates; Prospective Studies; Recurrence; Retreatment; Risk Assessment; Statistics, Nonparametric; Tenofovir; Transplantation Immunology; Treatment Outcome | 2014 |
Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; India; Male; Middle Aged; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2013 |
Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Female; Graft Survival; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2015 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Professional-to-Patient; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Viral Load; Viremia | 2014 |
Mechanisms of hepatitis B virus resistance development.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtricitabine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Inflammation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; tat Gene Products, Human Immunodeficiency Virus; Tenofovir; Virus Replication; vpr Gene Products, Human Immunodeficiency Virus | 2014 |
Hepatitis B virus drug resistance tools: one sequence, two predictions.
Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Telbivudine; Tenofovir; Thymidine | 2014 |
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Recurrence; Tenofovir; Withholding Treatment; Young Adult | 2014 |
Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2014 |
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?
Topics: Adenine; Adult; Body Mass Index; Bone Density; Cross-Sectional Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk; Risk Assessment; Tenofovir | 2015 |
[Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Young Adult | 2014 |
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Netherlands; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Spain; Tenofovir; Time Factors; Turkey; White People | 2015 |
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV; Humans; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir; Young Adult | 2014 |
Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Antiviral Agents; Asian People; Bone Density; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Osteoporosis; Phosphates; Prospective Studies; Renal Reabsorption; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B.
Topics: Adenine; Aged, 80 and over; Antiviral Agents; Fanconi Syndrome; Fatal Outcome; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2014 |
Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2014 |
Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Hepatitis B, Chronic; Humans; India; Liver Cirrhosis; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Organophosphonates; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir; Thymidine | 2014 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Gastrointestinal Diseases; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2014 |
Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
Discovering novel direct acting antiviral agents for HBV using in silico screening.
Topics: Adenine; Albumins; Animals; Antiviral Agents; Binding Sites; Cells, Cultured; Chimera; Databases, Protein; Drug Design; Drug Discovery; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Ligands; Liver; Mice; Middle Aged; Molecular Docking Simulation; Organophosphonates; Protein Binding; Real-Time Polymerase Chain Reaction; Tenofovir | 2015 |
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2014 |
Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection.
Topics: Adult; Antiviral Agents; Female; France; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Male; Middle Aged; Tenofovir | 2015 |
Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Treatment Outcome | 2014 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
[Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B].
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nucleosides; Retrospective Studies; Sex Factors; Tenofovir; Treatment Outcome; Young Adult | 2015 |
HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Gene Products, pol; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Organophosphonates; Retrospective Studies; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2015 |
Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection.
Topics: Adult; Antiviral Agents; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; Nephrotic Syndrome; Tenofovir | 2015 |
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; ROC Curve; Tenofovir; Treatment Failure; Treatment Outcome | 2015 |
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Female; Genotype; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Live Birth; Male; Middle Aged; Mutation; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Vaccination; Viral Load; Young Adult | 2015 |
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viral Matrix Proteins; Young Adult | 2015 |
Renal proximal tubular dysfunction due to tenofovir in a patient with chronic hepatitis B monoinfection.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Immunocompromised Host; Male; Middle Aged; Phosphates; Tenofovir; Treatment Outcome | 2015 |
[The possibility of tenofovir monotherapy as a rescue therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2015 |
Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir disoproxil fumarate treatment in HbeAg-positive patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Hospitals, Teaching; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey; Viral Load | 2015 |
Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2015 |
[Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures].
Topics: Adenine; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Nucleotides; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Organophosphonates; Remission Induction; Tenofovir | 2014 |
Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir | 2015 |
Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Republic of Korea; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2015 |
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retreatment; Tenofovir; Time Factors; Treatment Outcome | 2015 |
Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma.
Topics: Adenine; Bone Marrow; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Organophosphonates; Remission Induction; Splenic Neoplasms; Tenofovir; Viral Load | 2015 |
Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian; Biomarkers; Databases, Factual; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2015 |
Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Remission Induction; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Coinfection; Cross-Sectional Studies; Elasticity Imaging Techniques; Female; Ghana; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
Topics: Antiviral Agents; Calibration; Chemistry Techniques, Analytical; Chromatography; Chromatography, High Pressure Liquid; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Nucleosides; Reproducibility of Results; Tandem Mass Spectrometry; Telbivudine; Tenofovir; Thymidine | 2015 |
Tenofovir-best hope for treatment of chronic hepatitis B infection?
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Seroconversion; Tenofovir; Treatment Outcome; Young Adult | 2015 |
Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?
Topics: Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Withholding Treatment | 2015 |
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Imaging Techniques; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Follow-Up Studies; Forecasting; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Italy; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Nucleosides; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Tenofovir | 2015 |
Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Nucleotides; Probability; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2015 |
Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?
Topics: Alanine Transaminase; Antiviral Agents; Central Nervous System Agents; Depression; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fumarates; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Tenofovir; Transaminases; Viral Load; Virus Activation | 2015 |
Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.
Topics: Antiviral Agents; Chemokine CXCL10; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2015 |
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
[Prevention of mother to child transmission of hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Viral Load; Young Adult | 2015 |
Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2016 |
Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Canada; Cohort Studies; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viremia | 2016 |
Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir.
Topics: Adult; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Male; Tenofovir | 2015 |
Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Coinfection; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Models, Biological; Nonlinear Dynamics; Renal Elimination; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand; Treatment Outcome | 2015 |
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Molecular; Organophosphonates; Tenofovir; Virus Replication | 2015 |
More Long-term Assessment of Transient Elastography Is Needed for HIV/Hepatitis B Virus-Coinfected Patients Undergoing Treatment With Tenofovir.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Tenofovir | 2016 |
Reply to Boyd and Lacombe.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Tenofovir | 2016 |
Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.
Topics: Academic Medical Centers; Adult; Alanine Transaminase; Antiviral Agents; Asian People; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Republic of Korea; Retrospective Studies; Tenofovir; Viral Load | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Turkey | 2016 |
Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure.
Topics: Adult; Antiviral Agents; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Tenofovir; Treatment Failure; Treatment Outcome | 2016 |
Tenofovir Therapy for Hepatitis B May Be Commonly Prescribed Without HIV Testing.
Topics: Antiviral Agents; Diagnostic Tests, Routine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Tenofovir | 2016 |
Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mice; Mice, SCID; Tenofovir | 2016 |
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Organophosphonates; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load | 2015 |
Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Topics: Antiviral Agents; China; Cost-Benefit Analysis; Drugs, Generic; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; National Health Programs; Quality-Adjusted Life Years; Tenofovir | 2015 |
Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.
Topics: Adult; Antiviral Agents; Creatinine; DNA, Viral; Elasticity Imaging Techniques; Fatigue; Female; Germany; Headache; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kidney Diseases; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Combination of Pegylated Interferon and Tenofovir for Hepatitis B Treatment: Screening and Counseling of Patients are Warranted.
Topics: Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Tenofovir | 2016 |
Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Hospitals; Humans; Incidence; Kidney Diseases; Lamivudine; Male; Middle Aged; Nephrons; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Telbivudine; Tenofovir; Thailand; Thymidine; Tropical Medicine | 2015 |
AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.
Topics: Animals; Antiviral Agents; Biological Therapy; Biomarkers; Dendritic Cells; Disease Models, Animal; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Immunity, Cellular; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lymphocyte Activation; Marmota; Mice; Mice, Inbred BALB C; Mice, Transgenic; Parapoxvirus; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha; Vaccines, Inactivated; Virus Replication | 2015 |
Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir.
Topics: Adult; Age Factors; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins, HDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; Retrospective Studies; Tenofovir; Treatment Outcome; Virus Replication; Young Adult | 2016 |
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk; Tenofovir | 2016 |
Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Nucleosides; Nucleotides; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2016 |
Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
Topics: Adult; Coinfection; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Male; Tenofovir; Viral Load | 2016 |
Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.
Topics: Antiviral Agents; Coinfection; Defective Viruses; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2016 |
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Asthenia; Diarrhea; DNA, Viral; Female; France; Headache; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Hypophosphatemia; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Nausea; Prospective Studies; Seroconversion; Tenofovir; Treatment Outcome; Viral Load; Vomiting | 2016 |
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genetic Variation; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Young Adult | 2016 |
Sequential Therapy with PEG-IFN alpha-2a and Tenofovir in a Hepatitis B Virus-Infected African Man.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2015 |
Head-To-Head Comparison of Two Years Efficacy of Entecavir and Tenofovir in Patients with Treatment-Naïve Chronic Hepatitis B--The Real Life Data.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; Coinfection; Female; Genetic Variation; Genotype; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; HIV Infections; Humans; Male; Middle Aged; Quasispecies; Sequence Analysis, DNA; Tenofovir; Thailand | 2016 |
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine | 2016 |
Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Heart Transplantation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Viremia | 2016 |
Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Middle Aged; Nucleotides; Retrospective Studies; Survival Analysis; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA.
Topics: Adult; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2016 |
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Tenofovir; Treatment Outcome | 2016 |
[Effect of IL-28B polymorphisms on the natural course of HBV infection].
Topics: Adult; Antiviral Agents; Carrier State; Female; Guanine; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Lamivudine; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Real-Time Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine; Turkey | 2016 |
Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil.
Topics: Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Public Health; Tenofovir; Treatment Outcome; Viral Load | 2016 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2016 |
Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.
Topics: Adult; Age Factors; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome | 2016 |
Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF).
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunophenotyping; Killer Cells, Natural; Liver; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily C; NK Cell Lectin-Like Receptor Subfamily K; Phenotype; Tenofovir; Viral Load; Young Adult | 2016 |
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Creatinine; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Nucleosides; Nucleotides; Retinol-Binding Proteins; Retrospective Studies; Spain; Tenofovir; Young Adult | 2016 |
Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.
Topics: Antiviral Agents; Benzothiazoles; Costs and Cost Analysis; Diamines; DNA Primers; DNA, Viral; Drug Monitoring; Follow-Up Studies; Gambia; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organic Chemicals; Quinolines; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Senegal; Sensitivity and Specificity; Staining and Labeling; Tenofovir; Time Factors; Viral Load | 2016 |
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome | 2016 |
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.
Topics: Acute Kidney Injury; Aged; Antiviral Agents; Creatinine; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Tubules; Male; Microscopy, Electron; Middle Aged; Necrosis; Risk Factors; Tenofovir | 2016 |
Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Sustained Virologic Response; Tenofovir; Withholding Treatment | 2016 |
The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Postoperative Complications; Proportional Hazards Models; Recurrence; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome; Withholding Treatment; Young Adult | 2016 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Virus Activation; Young Adult | 2016 |
[Efficacy of tenofovir monotherapy or lamivudineadefovir dipivoxil combination therapy in treatment of lamivudine-resistant chronic hepatitis B].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2016 |
Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
Topics: Adult; Antiviral Agents; Drug Monitoring; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir | 2016 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir | 2017 |
Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2017 |
Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
The development of dry eye disease during tenofovir and entecavir therapy in a patient with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Dry Eye Syndromes; Female; Guanine; Hepatitis B, Chronic; Humans; Tenofovir | 2016 |
[Changes in serum β2-microglobulin, retinol-binding protein, and cystatin C and their value in identifying early renal dysfunction in patients with chronic hepatitis B undergoing tenofovir or entecavir monotherapy: a comparative analysis].
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Creatinine; Cystatin C; Female; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Predictive Value of Tests; Renal Insufficiency; Retinol-Binding Proteins; Serum Albumin; Tenofovir; Treatment Outcome | 2016 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepatocellular; Culture Media, Conditioned; DNA, Viral; Female; Gene Expression; Genotype; Guanine; Hep G2 Cells; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HT29 Cells; Humans; Interferons; Interleukins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Polymorphism, Genetic; Recombinant Proteins; Tenofovir; Up-Regulation; Young Adult | 2018 |
Treatment outcomes in treatment experienced and treatment naïve patients on Tenofovir disoproxil fumarate for chronic hepatitis B.
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2017 |
Peripheral Ulcerative Keratitis Secondary to Chronic Hepatitis B Infection.
Topics: Antiviral Agents; Corneal Ulcer; Cryoglobulinemia; Cyclophosphamide; Female; Glucocorticoids; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Middle Aged; Mycophenolic Acid; Ophthalmologic Surgical Procedures; Prednisone; Tenofovir; Vasculitis | 2017 |
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
Topics: Adenine; Adult; Antiviral Agents; Australia; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Tenofovir; Viral Load; Virus Activation | 2016 |
Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.
Topics: Antiviral Agents; Australia; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Markov Chains; Quality of Life; Tenofovir; Time Factors; Treatment Outcome | 2017 |
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Treatment Outcome; Viral Load | 2016 |
[A Case of Tenofovir-associated Fanconi Syndrome in Patient with Chronic Hepatitis B].
Topics: Antiviral Agents; Bone and Bones; Calcifediol; Fanconi Syndrome; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; Middle Aged; Osteomalacia; Phosphates; Renal Reabsorption; Tenofovir | 2016 |
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Research Design; Risk Assessment; Spain; Tenofovir; Treatment Outcome | 2017 |
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2016 |
Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Republic of Korea; Tenofovir | 2017 |
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
Topics: Adenine; Adult; Drug Combinations; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Pilot Projects; Tenofovir | 2016 |
Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Kaplan-Meier Estimate; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2017 |
Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Nucleotides; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Tenofovir; Treatment Outcome | 2017 |
Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Topics: Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Italy; Markov Chains; Quality-Adjusted Life Years; Tenofovir; Treatment Outcome | 2017 |
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV Infections; Humans; Male; Middle Aged; Switzerland; Tenofovir; Viral Load; Virus Replication | 2017 |
Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Receptors, Antigen, T-Cell, alpha-beta; Seroconversion; T-Lymphocytes, Regulatory; Tenofovir; Young Adult | 2017 |
Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Propensity Score; Tenofovir; Treatment Outcome; Viral Load | 2017 |
HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
Topics: Adult; Amino Acid Substitution; Clonal Evolution; Demography; Epitopes, B-Lymphocyte; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hydrophobic and Hydrophilic Interactions; Lamivudine; Mutation; Protein Domains; Quasispecies; RNA-Directed DNA Polymerase; Tenofovir; Treatment Outcome; Viral Proteins | 2017 |
[Chronic hepatitis B. Tenofovir--the right choice from the beginning].
Topics: Adenine; Antiviral Agents; Drug Approval; Europe; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
[Drug approval studies of Viread. As effective in HBeAg positive as also in HBeAg negative patients].
Topics: Adenine; Antiviral Agents; Drug Approval; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Viral Load | 2008 |
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Animals; Antigens, Viral; Antiviral Agents; Deoxycytidine; Disease Models, Animal; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Marmota; Organophosphonates; RNA, Viral; Rodent Diseases; Tenofovir; Virus Replication | 2008 |
Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2008 |
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mutation; Organophosphonates; Promoter Regions, Genetic; Tenofovir | 2008 |
Two-year data released on Viread for chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis B, Chronic; Humans; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
[Protocol for the antiviral therapy of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2008 |
Chronic hepatitis B--new goals, new treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Viral Load | 2008 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2009 |
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2009 |
[New molecules in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Topics: Adenine; Administration, Oral; Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Markov Chains; Models, Economic; Organophosphonates; Retrospective Studies; Salvage Therapy; Secondary Prevention; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2009 |
[Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Resistance, Viral; Evidence-Based Medicine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2009 |
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir | 2009 |
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Viremia | 2009 |
Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
Topics: Adenine; Antiviral Agents; Bone and Bones; Bone Diseases; Double-Blind Method; Drug Approval; Europe; Fractures, Bone; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viremia; Virus Replication | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2009 |
Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Gene Amplification; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2009 |
Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.
Topics: Adenine; Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Molecular Sequence Data; Mutation, Missense; Organophosphonates; Selection, Genetic; Sequence Alignment; Tenofovir; Treatment Failure; Viremia; Young Adult | 2010 |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
Topics: Adenine; Antiviral Agents; Asia; Cost-Benefit Analysis; Decision Support Techniques; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Germany; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Nucleosides; Organophosphonates; Pyrimidinones; Salvage Therapy; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; United States | 2010 |
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Probenecid; Secondary Prevention; Tenofovir | 2010 |
The curative efficiency of tenofovir for patients with chronic hepatitis B after failure of nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Remission Induction; Tenofovir; Treatment Failure | 2010 |
Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
Topics: Adenine; Adult; Antiviral Agents; Female; France; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Surveys and Questionnaires; Tenofovir | 2010 |
Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Cost-Benefit Analysis; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; State Medicine; Tenofovir; United Kingdom | 2010 |
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Combinations; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2010 |
[Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Tenofovir; Treatment Failure; Viral Load | 2010 |
[Treatment of chronic hepatitis B. High response rate in general practice].
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Germany; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Organophosphonates; Patient Care Team; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2010 |
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir; Viral Load; Viral Proteins; Virus Replication | 2011 |
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Young Adult | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Virus Replication; Young Adult | 2011 |
Virologic and clinical outcomes in HIV/HBV coinfected patients on tenofovir-containing HAART.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Organophosphonates; Tenofovir | 2010 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; DNA, Viral; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2010 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
[Analogs combination therapy in chronic hepatitis B: when and how?].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.
Topics: Adenine; Adult; Chronic Disease; Female; Graft vs Host Disease; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Activation | 2011 |
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome | 2011 |
Tenofovir salvage for nucleoside experienced patients: muddy waters?
Topics: Adenine; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir | 2011 |
Hyperlipidemic acute pancreatitis: a possible role of antiretroviral therapy with entecavir.
Topics: Abdominal Pain; Acute Disease; Adenine; Adult; Alcoholism; Antiretroviral Therapy, Highly Active; Critical Care; Diabetes Mellitus, Type 2; Fever; Guanine; Hepatitis B, Chronic; Humans; Hyperlipidemias; Hypertriglyceridemia; Male; Organophosphonates; Pancreatitis; Plasmapheresis; Reverse Transcriptase Inhibitors; Tenofovir; Tomography, X-Ray Computed; Triglycerides | 2011 |
Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antigens, CD; Case-Control Studies; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Flow Cytometry; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoassay; Male; Middle Aged; Organophosphonates; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Tenofovir; Viral Load | 2011 |
[Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir | 2011 |
Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Enzymes; Female; France; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organ Transplantation; Organophosphonates; Pilot Projects; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2011 |
Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure.
Topics: Adenine; Antiviral Agents; End Stage Liver Disease; Guanine; Hepatitis B, Chronic; Humans; Liver Failure, Acute; Organophosphonates; Tenofovir | 2011 |
Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Bone Marrow; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Italy; Organophosphonates; Tenofovir; Treatment Outcome; Viremia | 2011 |
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2011 |
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Case-Control Studies; Female; Gene Products, pol; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Linear Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Antiviral drug resistance testing in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Data Collection; Decision Making; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Surveys and Questionnaires; Tenofovir; Treatment Outcome; Viral Load | 2012 |
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Genotype; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2011 |
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2011 |
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Internationality; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viremia; Young Adult | 2012 |
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis B, Chronic; Humans; Insurance Coverage; Lamivudine; Liver Cirrhosis; National Health Programs; Organophosphonates; Tenofovir | 2011 |
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Hepatitis B virus; Hepatitis B, Chronic; Humans; Insurance, Health, Reimbursement; Male; National Health Programs; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
Topics: Adenine; ADP-ribosyl Cyclase 1; Adult; Antiviral Agents; Biomarkers; CD28 Antigens; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Flow Cytometry; Forkhead Transcription Factors; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunity, Cellular; Interleukin-2 Receptor alpha Subunit; Kinetics; Male; Membrane Glycoproteins; Middle Aged; Organophosphonates; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Tenofovir; Treatment Outcome; Turkey; Viral Load; Virus Replication | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2012 |
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2012 |
Safety of long-term nucleos(t)ide treatment in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Evidence-Based Medicine; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Patient Safety; Risk Assessment; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Tubules; Male; Middle Aged; Organophosphonates; Phosphates; Renal Insufficiency; Tenofovir; Time Factors; Uric Acid | 2012 |
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Assessment; Tenofovir; Young Adult | 2012 |
Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Young Adult | 2012 |
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir.
Topics: Adenine; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Another drug in the armamentarium to combat hepatitis B virus in adolescents.
Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Current practice of chronic hepatitis B treatment in Southern Italy.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Italy; Lamivudine; Male; Middle Aged; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Patterns, Physicians'; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Young Adult | 2012 |
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Cells, Cultured; DNA, Viral; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-1; Lamivudine; Organophosphonates; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Viral Load; Young Adult | 2012 |
Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Netherlands; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Telbivudine; Tenofovir; Thymidine | 2012 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
Scar undone: long-term therapy of hepatitis B.
Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Interferons; Kidney Diseases; Liver; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2012 |
Should chronic hepatitis B be treated as early as possible?
Topics: Adenine; Adult; Antiviral Agents; Belgium; Cost-Benefit Analysis; Early Diagnosis; Guanine; Health Care Surveys; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Markov Chains; Middle Aged; Organophosphonates; Quality of Life; Secondary Prevention; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Gene Products, pol; Genetic Association Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Male; Middle Aged; Molecular Typing; Organophosphonates; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; Sequence Analysis, DNA; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2013 |
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Thailand; Treatment Failure; United States | 2013 |
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Sampling Studies; Severity of Illness Index; Tenofovir; Treatment Outcome; Viral Load | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2004 |
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
Topics: Adenine; Anti-HIV Agents; Drug Eruptions; Hepatitis B, Chronic; HIV Infections; Humans; Lichenoid Eruptions; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Tenofovir therapy for lamivudine resistance following liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome | 2004 |
Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Marmota; Organophosphonates; Tenofovir; Treatment Outcome; Viremia; Virus Replication | 2005 |
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; Female; Genes, pol; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Viremia; Virus Replication | 2005 |
Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication.
Topics: Adenine; Antiviral Agents; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2006 |
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
Variant of hepatitis B virus with primary resistance to adefovir.
Topics: Adenine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Viremia | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Regression Analysis; RNA, Viral; Statistics, Nonparametric; Tenofovir; Treatment Outcome | 2006 |
A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
Topics: Adenine; Adult; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?
Topics: Adenine; Adult; Drug Resistance, Multiple, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Reversibility of cirrhosis in HIV/HBV coinfection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Organophosphonates; Platelet Count; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Health Care Surveys; Hepatitis B Vaccines; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tenofovir; United States | 2007 |
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Topics: Adenine; Adult; Arabinofuranosyluracil; Base Sequence; Cell Line, Tumor; Cloning, Molecular; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Transfection; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load; Virus Replication | 2008 |
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
[Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B, Chronic; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2008 |
Europe extends Viread indication for chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |